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Oral presentationsOral Presentabons: LUNG CANCER 3
001 VINORELBINE (VNR) PLUS BEST
SUPPORTIVE CARE (BSC) V'S BSC LN THE
TREATMEN`T OF ADVANCED NON- SMALL
CELL LUNG CANCER (NSCLC) ELDERLY PATIENTS (PTS).
RESLITS OF A PHASE III RANDOMIZED TRIAL.
C.Gridelli, G.P.Ianniello, L.Maiormno, L.Brancaccio, S.Cigolari, D.Bi-
lancia, R.Aiello, L.Zuccarino, T.Pedicini, S.Zonato, G.L.Pappagallo,
S Monfardini, A.Rossi, C.Gallo and F.Perrone on behalf of the ELVIS
(Elderly Lung cancer Vinorelbine Italian Study) Investigators.
Background. VNR is a well tolerated and active treatment for
advanced NSCLC elderly patients (Eur J Cancer 1997,33A:392-397).
Aim. To determine whether VNR improves quality of life (QoL) and
survival of advanced NSCLC elderly pts as compared with BSC.
Methods. Multicenter randomized trial. Pts aged 70 or more, stage IV
or IIIB (unsuitable for curative radiotherapy), ECOG PS <2, chemo
naive were eligible. VNR was given at 30 mg/i2 i.v. day I and 8, every
3 weeks for 6 cycles. A study size of 350 pts was planned using QoL
(EORTC QLQ C-30/LC13) as primary end-point. Three interim
survival analyses were planned, using an alpha-spending function based
on O'Brien-Fleming design. Randomization was centralized, with a
miimization procedure accounting for center, stage and PS as strata.
Results. Investigators, blinded to results, decided to stop the trial at
Nov 97. Thus, second interim analysis became the final one From April
96 to Nov 97, 191 pts were randomized. Survival analysis on 161 pts
randomized until June 97 (followed-up for at least 18 weeks) showed:
median survival 27 vs 21 weeks, 6-mos survival 54% vs 39%, 1 year
survival 270°Z0 vs 5%, for VNR and BSC, respectively (P=0.04).
Baseline characteristics of pts are well balanced in the two arms.
Overall median age (range): 74 yrs (70-86), male gender- 870%a, stage
I: 73%0 PS (0/1/2): 180/580o/240//o. In the VNR arm a 200o response
rate (950/o CI:12-32) was found. Toxicity was rare- G4 neutropenia,
G3-4 constipation and G3 alopecia (4% of pts each), G4 leukopenia,
G3 anemiia and G3 vomiting (1% of pts each). QoL analysis will be
ready for the meeting. Conclusion. Single agent VNR improves
survival of advanced NSCLC elderly pts, without significant toxicity.
The magnitude ofthe effect on survival is similar to that reported with
cisplatinum-based polychemotherapy in advanced NSCLC adult pts
003 PHXSE I STUDIES EVALUATING THE VCO_Nffl-ATION-OF GE-NICITANE -AN-
C-AROPLATIN IN NSCLC.
V Potter. J Carmichael'. P Woll'. L Osbome'. L Andrews'. JE
Stickland. CRC Department of Clinical Oncolo -. Citx
Hospital. Nottingham. -Eli Lilly & Company Ltd.
Presviously untreated patients with NSCLC were administered a
combination ofgemcitabine at a dose of 1gm' on days 1. 8. and 15 of
a 28 dav cycle. with carboplatin being given prior to the gemcitabine
on day 1. 13 patients (median age 64) with stage fib IV disease
received a median of3 cycles (1-6). Carboplatin dosingwas based on
the Calsert formula. starting at an AUC 4.0(3 pts) and no toxicity was
seen. Dose limiting myelotoxicity occurred at carboplatin AUC 5.2
10 pts). At this dose grade [I IV neutropenia and thrombocytopenia
occurred in 5800 and 35.500 of cycles respectively. To determine
w-hether the toxicities were sequence dependent 9 patients (median
age 58) w-ere treated w-ith gemcitabine prior to the carboplatinonday I
usme the same doses. Grade [I IV neutropenia and
thrombocvtopenia was seen in 50.30o and 43.70o of cycles
respectixelv. This cohort received a median of 4 cycles (2-6). Non-
haematological side effects were rare. mild lethargy being the most
frequently reported. Pharmacokinetic studies were performed on all
patients. initial evaluation showed no interaction between the drugs on
gemcitabine or carboplatin pharmacokinetic profiles. Although
efficacy was not the primars endpoint in these phase I studies higher
response rates were seen with the sequence gemcitabine carboplatin
with 4 PR (3 confirmed) versus 3 PR (1 confirmed). Currentlyu we are
esaluating the administration of gemcitabine 1gm' on days 1. 8. 15
esery 28 days with carboplatin AUC 5 given after gemcitabine on day
1. a second cohort of 9 patients will receive gemcitabine 1a m' gaiven
on day-s 1 and 8 esery 21 days with carboplatin AUC 5 follow'in
cemcitabine on dan 1.
002 NANELBIN'E IFOSFANMIDE
- CISPLAThN (NIP) IN LOCALLY ADVANCED NSCLC. M. Gottfried,
A. Yelih Y. Shapira. S. Todesco. F.M. Delgado.
Y. Rozenman. HJ. Brenner- Tel Hashomer - Israel
This clinical trial was performed in a neoadjuvant setting for locally
adsanced NSCLC. The primary measures of evaluation were clinical and
histological response rate (RR). time to progression. survival and tolerance
Three induction cycles ofN 25 mg m2 on day 1 and 5. P 80 mgm2 on day 1
and IFOS/MESNA 3 g/m2 day 1 every 21-day were administered. Between
06,95 and 09/97. 32 pts have been included. There are 31 pts evaluable for
tolerance and response. (1 pt ineligible, stage IV): 25 males and 6 females.
median age 56 y (40-75 y): PS 0: 520/o PSI: 48%. T3 NO: 36°o: T2 or
3 N2: 58°o T4 NO: 6°o All pts who were node positise on chest CTscan had
mediastinoscopy before entering the study to confirm the extent ofdisease.
Tolerance : A total of 92 evaluable courses have been administered.
median number of courses. 3 (2 - 3). The maximal toxicities observed
were Febrile neutropenia requiring 48 hours hospitalisation (G4): 1300.
G 2 anaemia: 14% ofpts. There was G 3 alopecia in 26 31 pts. 12 pts and
I pt had G2 and G3 emesis respectiselv
Results.: 18 pts achieved partial response. 1 pt complete response The
overall response rate was 61%. 29% had stable disease and 10°o
progressed. All responses were histologically confirmed. Among the 13 pts
w-ith mediastinal lymphnode involvement. confirmed by mediastinoscopv.
s-ho underwent surgery 10 pts (77 0/'O) were downstaged (node negatise)
histologically confirmed. The median time to progression is estimated at 40
weeks, 1 year survival 65% and overall survival is not reached, so far.
This study confirms that NIP is well tolerated and is an useful neoadjuvant
therapy proViding favorable results in the management oflocally advanced
NSCLC. This trial is still ongoing and the next step will be a randomised
Phase m study to evaluate adjuvant therapy after this induction
combination.
PRE-OPERATIVE CHEMOTHERAPY IN EARLY 004 STAGE RESECTABLE NON-SMALL-CELL LUNG
CANCER: A RANDOMISED FEASIBILITY STUDYt
JUSTIFYING A MULTICENTRE PHASE III TRIAL. R.H. de Boer'. P.
Goldstraw-. U. Pastorinno. M.E.R O'Brien'. F. Ramage'. S. Ashley' and
I.E. Smith'. 'Dept of Medicine. Royal Marsden NHS Trust. Fulham Rd.
London SW3. -Dept of Thoracic Surgery. Royal Brompton Hospital.
London SW3.
Surgical resection offers the best chance for cure for early stage non-
small-cell lung cancer (NSCLC. stage 1.. II IlA). but the 55 ear sursisal
rates are only moderate. with systemic relapse being the major cause of
death. Pre-operatise (neo-adjusant) chemotherapx has shown promise
in small trials restricted to stage IIIA patients. We beliese similar trials
are now appropriate in all stages ofoperable lung cancer.
.tfethods - A feasibility study was performed in 22 patientswith earls
stage (IB. II. IIIA) resectable NSCLC: randomised to either three cscles
of chemotherapy (mitomrycin-C 8 mgirn'. siinblastine 6 megrmn. and
cisplatin 50 mg/mr) followed by surgerv (n=I1). or to surgery alone.
Feasibilitv was the main endpoint. Secondanr endpoints included
response, symptom control. quality of life. resectabilits. toxicits and
surgical complications.
Results - 22 out of 40 eligible patients agreed to participate (feasibilits
55%) and all complied with the full treatment schedule. All
symptomatic patients achiesed either complete (50%) or partial
(50%) relief of tumour-related symptoms with pre-operatise
chemotherapy. 55%achiesed objectise tumour response. and a further
27% minor tumour shrinkage: none had progressive disease. Partial
pathological response was seen in 50/o. No ses-ere (WHO grade III-IV)
toxicities occurred. No significant deterioration in quality of life was
detected during chemotherapy.
Conclusion - Pre-operatise MVP chemotherapx is feasible in earls
stage NSCLC. and this studs has now been initiated as a LK-wide M1RC
phase III trial.4 Oral Presentations: LUNG CANCER
A RANDONISED STUDY OF SRL172 (MYCOBACTERIUM
005 VACCAE) INPATIENTS WITH ADVANCED LUNG
CANCER TREATED WITHCHEMOTHERAPY.
A Webb'. M AI-Mcoudhri'. BE sobibicl,3. A Noton'. KPries'. C R-a. R
Mendcs'. S Ashk'ey. LE Snuth'. MEROBricn'-. 'ROya Marsdcn NHSTnisi Sunon:
2Mid KentOncolMb Centrc, MabsioneDc;p ofMoeularMcibcine, King's College.
Introducon- SRL172 is a preparation of heat killed Myeobacierirnm vuccae.
When used with autologous cells in aruinial models, It proved to be a very potent
Immunological adjuvant- In human studies, no systemic toxicity has been
observed and local toxicity is mild allowing repeat administris. This study
was designed to test the feasibility ofcombining SRL172 withdchmoherapy in
28 patients with symwptomatic NSCLC or mesotheloma with a view to using it
as an adjuvant with allogenic cell limes as atumour vacine.
Mehiods patients were randomised to receive chenmohrapy (NIVP) with
(n=13) or without SRL172 (n=15). SRL172 we given intudermally on day 0,
weeks 4, 8 and then 3-6 monthly. The response was assessed using CT
scanning every 2 courses.
Results: The treament arm-s were well balanced with respect to tumour stage,
performncwe staus, age and sex distribuos. The response rate for MVP
alone was 33% (5/15 PR), and for MVP + SRL172 was 54% (7/13 PR)
(p=0.23). Toxicity assessment showed no difference between arms. 2 patients
on the MVP + SRL172 arm underwent curative surgery after treament
downstaging (1 stage mA, 1 stage HIB). Overall survival wa 7 months for
MVP and 9.5 months for MVP + SRL172 (p=O 05).
Conclusion: the combination of NMVP and SRL172 was well tolerated The
higher response rate and better survival figures with the MVP + SRL172
combination are interesting and provocanve and will be fuer investigated in a
larger multicentre randomised study The actual mechanism of a potential
interaction will now be studied in animal models.
We are grateful for support from Stanford Rook Ltd.Oral Presentatons: LYMPHOMA 5
006 THE CHANGING FACE OF MANTLE
CELL LYMPHOMA. 1R.E.Hough,
2J.R.Goepel, 1P.C.Lorigan, 3E.A.Vandenberghe,
4J.E.Allen, 4D.W.Hammond, IB.W.Hancock. lYorkshire Cancer
Research Department Of Clinical Oncology, Weston Park Hospital,
Sheffield. IDepartment of Pathology, IDepartment of Haematology,
4Institute ofCancer Studies, Royal Hallamshire Hospital, Sheffield.
Introductio: Mantle cell lymphoma (MCL) has historically been
classified and treated as a low grade subgroup of Non-Hodgkin's
lymphoma (NHL) because of its' innocuous histological appearance.
It is now clear that this group of patients fair much worse than those
with other low grade NHL subtypes. Approach to therapy is
changing to include more aggressive regimens, but the optimal
strategy remains ill-defined.
Aim: To review the management and outcome of 65 consecutive
patients treated at Weston Park Hospital, Sheffield.
Patients And Results: 47 male and 18 female patients presented
between March 1981 and February 1998. Mean age was 60.8 years
(range 25-84 years). 60 patients had a perfomiance status of 0-2, 33
patients had stage IV disease (including 23 with bone marrow
infiltration) and 19 described 'B' symptoms. 9 patients were anaemic,
12 had an elevated ESR, 15 an elevated LDH, 20 an abnormal
lymphocyte count and 13 abnonmal immunoglobulin profile. Sites of
presentation included the lymphoreticular system (35), gastrointestinal
system (17), soft tissue (8) and bone (5). Initial therapeutic approach
included observation alone (8), chlorambucil (16), locoregional
radiotherapy (17), COP (5), CHOP (10), other combination
chemotherapy (7) or radiotherapy in addition to chemotherapy (2). 5
patients have subsequently received high dose chemotherapy. 22
patients are still alive at a median interval of 27.3 months (range 10-
179 months). 11 of these are still in complete remission. 43 patients
have died at a median interval of 24.4 months (range 1-95 months).
Death was related to progressive disease in 34 cases, treatment in 5,
myocardial infarction in 1 and unknown in the remaining 3.
Conclusions: MCL is an aggressive malignancy with a poor
prognosis more typical of high grade NHL. Identification ofeffective
therapeutic strategies are urgently required.
RA-NDONI1ZED STLDYI OF \INORELBMNE OR \TDESPxE
00V 'WITH CISPL.ATIN AN-D NIITOMY)CA- .AS JNDICTION
CHEMOTHERAPYoiA NSCLC. K Furse. M. Kawahara.
Y, Niahiaki. T. Holm'. N. Saijo.K Haseg K Okshio & H. Nutani. Japan
To evaluate new drugs in combination with cisplatin and mitomycim in
advanced stage IIIB and IN non-small cell lung cancer (NSCLC). we
conducted a multicenter randomized study. Eligible patients (pts) were
stage HIIB or IV NSCLC. performance status (PS) 0 or 1. and were
previously untreated Pts were randomized to receive vinorelbine 25 mg m'
on day I and 8 (arm A) or vindesine 3 mgm2 on day 1 and 8 (arm B).
Cisplatin 80 mg m' and mitomycin 8 mg m2 were given in both groups on
day 1. and cycles were repeated every 4 weeks. Results:
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Treatment arms A and B were well balanced in characteristics such as
gender. age. histology. stage and PS. One hundred and sexen pts w-ere
accrued To date. preliminary response rate is 57 %0 for arm A and 38 for
arm B This difference in response rate is significant (p=0 04) Althouch
the median follow-up time is 8.0 months. the median suri-vnal time is > 12
months in arm A and significantly longer than 8.0 months in arm B
(p=0 017). Toxicities during chemotherapy have been similar and tolerable
in both arms There was one treatment-related death in arm B These
preliminarx results suggest that arm A including navelbine is more actixe
then arm B includinz vindesine Further studs of arm A and concurrent
radiotherapy in unresectable stage III isx-warranted
EXTRANODAL LYMPHOMA - NO CASE FOR 007 COMPLACENCY. L Dobson, H Hancock, P S Evans,
M H Robinson and B W Hancock. Yorkshire Cancer
Research Dept. of Clinical Oncology, Weston Park Hospital,
Sheffield, UK.
Pugse: Elxtranodal lymphomas account for 17-41% of all cases of
NHL; however, their natural historv is still not well understood. We
reviewed all new cases seen bv our group from 1970-95.
Methods: All cases of lymphoma referred to the SLG (totalling 2,100
cases of NHL) are recorded on a dedicated database; demographic,
staging and follow-up data for all loco-regional (stage I, II) extranodal
(EN) and nodal (N) NHLs were extracted and analysed. Treatment
policy was to gixe radical involved field radiotherapy wherever
pOSsible.
site (n) Age Sex Stage Sympt- Histol. mean
<45< NI F I 11 oms Grade sunr-
A B I 1I rval
ENGI(95) 15 80 49 46 43 49 68 24 27 66 57.25
H&N(188) 28 160 94 94 124 60 175 9 60 120 64.77
Skin(36) 8 28 19 17 28 7 33 2 12 19 56.31
CNS(35) 9 26 22 13 33 1 30 4 8 26 46.28
Other(57) 8 49 31 26 37 20 52 5 9 47 52.37
All
EN(411) 68 343 215 196 265 137 358 44 116 278 59.1
Nneck(78) 16 62 42 36 76 2 78 00 30 45 68.38
other(64) 13 51 29 35 61 3 59 5 31 32 65.95
AllN(143) 29 114 71 72 137 5 137 5 61 T7 67.3
AIl(554) 97457 286268 402 142 495 49 177355 61.3
Unfavourable prognostic indices were older age, male sex, stage II, B
symptoms, Grade II histology, low Hb. low albumin and raised ESR.
Conclusion: The sunrival for EN NHL varies between sites - the most
favourable being head and neck (H&N), the least favourable was CNS
The overall sun-is-al of locoregional EN NHL was less than to that of
nodal NHL. Prognostic indicators for sun ival were those
acknowledged for all NHLs (age. sex, stage, symptoms. histology,
grade, Hb, ESR albumin).
)9%9 ANALYSIS OF SECOND M&ALIGNANCY
009 AFTER HODGKIN'S DISEASE. A Horwich. A J Swerdlow-. J A Barber. G Vaughan Hudson
R K Gupta4. D Linch'. D Cunningham'. T A Listcr4. Roval Marsden
NMHS Trust'. London School of Hygiene & Tropical Medicine-.
B'NLI'. St Bartholomew's Hospital4.
To analyse second malignancy (SM) risk. especiall>N with
respect to age and time after treatment for Hodgkin's disease (HD). we
rexiewed 5519 patients treated between 1963-1993 within hospitals in
the British National Lymphoma Investigation BN'LI (n = 3772). The
Royal Marsden Hospital (n = 1039) and St Bartholomew's Hospital (n
= 708.
There were a total of 322 second malianancies (excluding non-
melanoma skin cancer) representing a relative risk (RR) of 2.9 (95%
CI 2.6 - 3.2). including 44 leukaemias. RR 14.6 (95%c CI 10.6 - 19 5
and 50 non Hodgkin's lymphomas. RR 14.1 (95% CI 10.4 - 18.5).
The risk of SM was higher in patients treated at a younger age.
w-ith for example. a RR 26.1 (12.5 - 47.0) in age < 15 years. a RR of
7.0 (5.1 -9.3) for those 15 - 24 years. and RR of 1.9 (1.6 - 2.4) for
those > 55 years. The RR of leukaemia and NHL was highest 5 - 9
xears after treament whereas for solid tumours the RR increased with
time after treatment.
We conclude that second malignancies are a significant and long terrn
problem after treatment for HD. with higher risk in younger patients.
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p value6 OralPresetaions: CUNICAL RADIOTHERAPY
ODONE PAIN TRIAL A PROSPECTIVE RANDOMISED TRIAL
010 COMPARING A SHIGLE DOSE OF 8 GY AND A MULTIFRACTIO RADIOTHERAPY SCHEDULE IN ThE
TREATMDW OFMETASTATIC BONE PAIN.
(JR Yuidd Royal Muaden NHS Trust, Sulm, SuTey, UK, on behalf ofthe Boxmpsin
Trial Group)
Background: Between 1992 and 1997, 762 patients with painfui
bone metastases were randomised to receive either a multifraction
regimen or 8Gy single fiaction after written informed consent. The
primary endpoints ofthe trial were pain reliefat I month and duration
of pain relief to 12 months as recorded on patient self-asse
questionnaires. These were completed prior to randomisatkio, at 2
weeks and 4 weeks, monthly until month 6 and then at 8 months, 10
months and 12 months.
Results: The median age of the patients at randomisation was 67
(range 20-91) and the ratio of male to female was roughly 1:1. The
most common primay sites of cancer were breast (37h/), prostate
(35%) and lung (12/.). The randonised sites of pain that occurred
most often were hlubar spine (19%/), hip (14%), pelvis (10%/.) and
ribs (101%). Patient compliance with the questionnaire remained in
excess of90h/othroughout the period ofthe study.
No s ally s f difference between the two regimens was
observed with regards to pain rel in particular the proportion of
patits experiencing pain relief at one month (58% single fiaction,
56% rlation), thoseexperiencing a subsequent return ofpain to
its original baseline level (34%, 36%) and any pain relief from
baseln (74%, 70h/)
Conclusion: The results indicate that a single firation of 8Gy is as
effective as a multifraction regimen in relieving metastatic bone pain
forup to 12 months aftertreatment.
012 CERVICAL NODE METASTASIS OFUNKNOWN PRIMARY SITE: THE ROYAL MARSDEN
HOSPITAL 15 YEAR EXPERIENCE.
ANJ Tutt, R. A'Hern, J.M. Henk. Head and Neck Unit
Royal Marsden Hospital NHS Trust, LondonSW3 6JJ.
PM Prophylactic radiation to sites of potential primary
disease within the pharynx causes ssantial morbidity and is
controversial. We describe our experence of managing cervical node
mestasis withoccultprimary avoidingpan-pharyngeal i iation.
Met s: We ientifi 53 patients, presenting between 1983 and 1998,
withcervicalmetasases, excluding the supraclavicularfossa, in whom no
primary wasidentified We exchxled patients with non Squamous/UCNT
histology or those where treatment intent was not curative. We thus
included41 patients, with medianfollow up of29 months.
Results Investigations inchxled EUA in 38 patients, with muiple
biopsies in32,andCTscanin32.TNMnodalstagewasNI in 8, N2a in
7, N2b in 8, N2c in 1, N3 in 13 and unavailabie in 1. Eighteen patients
hadextracapsularspread (ECS). Threepatients had neck dission alone,
13 had combined treatment and the Iremander radical radiotherapy. Of
s receiving radiotherapy the volume was limited to the ipatal
hemi-ek in 33. Nodal control in the neck was never achieved in 3
patients. A head and neck prmay sbsently became appent in 12
patients occurring in the tongue base in 6, nasopharynx in 2, tonsil in 2
and 1 each in the pyriform fossa and parotid, at a median interval of 51
weeks (range 15-325). These occurred within the radiatio field in 2
patients and adjacent to itin5. Radical treatment to the primary was given
in 10patients. Neckfailure occurred in 20 patients, 9 within the radiation
field, at a median interval of 59 weeks (range 15-325). One patien died
with an uncontrolled head and neckprimary, 10 with an uncontrolled neck
and 1 with both uncontrolled neck and primary. Three patients had neck
disease when lostto follow up. Actuarial overall survival at 3 and 5 years
was 63% (95% CI 45% - 64%) and 44% (95% CI 22% - 64%).
Conclusion: Selective avoidance ofpharyngeal ir tion after CT, EUA
and speculative biopsies is justified but we find the tongue base to be a
frequent site of subsequent primary. This site may be better evaluated by
MRI IPET imaging. Only onepatient died with uncontrolled local disease
at the primary site alone. The patient also had Mytaic disease. This
justifies the approach to managementadopted. Uncontrolled neck disease
atdeath is a more frequent problem thanlack ofcontrol at theprimary site.
EFFECT OF GAP NUMBER AND DURATION
011 ON OUTCOME OF RADIOTHERAPY IN
LARYNGEAL CANCER M van Daesdonk, J.
Glaholm, D. Moffat, ND James. CRC Institute for Cancer Studies and
Queen Elizabeth Hospital, Birmingham.
Aim: Treatment interruptions are known to affect the outcome in head
and neck cancer. We have investigated the effects of interruptions on
disease free survival in patients receiving radical radiotherapy over 3 to
4 weeks ratherthan 6-6.5 weeks.
Methods: The records of all patients who received primary radical
radiotheapy for squanous cell carcinoma of the larynx at the Queen
Elizabeth Hospital, Birmingham, between 1991 and 1994 were
examined. The following items were recorded: age, sex, stage and
treatment details, together with dates of recurrence, death and cause of
death.
Results: A total of 337 patients were treated during the study period.
The median age for all patients was 66.16 years. The majority of
patients received either 5OGy in 15 fractions or 55Gy in 20 fractions.
Actuarial disease free survival at 2 years was 70% for node negative
and 23% for node positive patients. 323 patients had at least one gap in
treatment. There was no significant effect from prolongation of the
overall treatment time (p=0.62) on disease free survival. There was
however a significant correlation between the number of gaps and
outcome with patients experiencing 3 or 4 gaps in their treatment
having significantly worse disease free survival compared to those
patients with 0-2 gaps (p=0.049). The overwhelming majority of gaps
in treatment were due either to service days (241 interruptions) or to
bank holidays (105 interruptions) only 18 interruptions were due to the
patient being too ill to attend.
Condusios: For patients receiving radiotherapy using treatment
schedules of 3 to 4 weeks, multiple gaps in treatment appear to be more
significant than overall treatment time in affecting outcome. This has
important implications for the organisation of treatment in busy
radiotherapy departments.
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AC~IRACY OF THORACIC RADIOTHERAPY: PPECTVE
014 OF 24 PATNTS TREATED WIT NON 014 PLLXAIW RA1OTH1tAPYFOR LUING CANCER, S.
Essapen, C. Knowles, A. Noman2 and D. Taie, 'Dept of
Radhapy and Oncology, Royal Norden NHlS Tnat, Surrey
SM2 SPT, UiK, 'Dept of S eis, Roal Marsden NlS Trut, Srrey 5M2 SPT, ULK
Alm: To prospectvety assess te accuracy of treatent set-up in radical
raditherapy for lung cancer.
Mehod: Initial evalution of portal imaging and veifiaton films proved
these methods inappropriate because of inadequate bony landmarks as
reeec points. Therefore, patients retumed to the simulator weeldy,
during their bteatmet, for four simulator check radiographs (SCRs). For
each 5CR, treatment parameters from the original simulator visit were
set, without fluorosopy. Twenty-four patients were studied, and 96 SCRs
were taken. Field pla errors (FPEs) were obtained by measuring
the displaement of field centres between the SCRs and the
corresponing original simuator radiograph (OSR). FPEs in anterior,
right-lelt (RL) and superior-inferior (SI) planes, and coronal otational
errors (CREs) were measured.
Results: In the arms down group (ADG) (12 patients with SCaC, treated
with parallel opposed fields), mean FPE was 0.43 an to the right of, and
0.36 an inferior to, the intended field centre. The mean CRE was 20,
with 40% of the films in this sub-group showing an error of >2°. In the
remaining 12 pabents (NSC3C) planned using computerised tomography
(arsf up group, AUG), mean FPE was 0.27cm to the right, and 0.5 an
inferioy. The mean CRE in this sub-group was 1°, with 23% of the films
showing a CRE of >20. In both patient groups, 28% of the measurements
showed a FPE of more than 0.5 an, and 3% and 4% in the ADG and AUG
respectively showed a FPE of more than 1 cn. No statstcally significant
differences were found between the FPEs in these two groups, although
there was an increased tendency for the FPEs to be displaced inferiorly in
the AUG. No patient factors predited for worse outcome in any
direction.
Conduslon: Despite no immobilisation device being employed, FPE was
within dinical tolerance (FPE <=0.5 an) in 72% of measurements. The
obvious concem is in the remaining 28% where the entire planning target
volume may fail to receive the tumouricdal dose, compromising tumour
control. CRE was worse in the ADG, probably because lteral tatoos are
not used for treawent set-up for AP/PA treatrmet portals. Quantifation
of FPE is critical for conformal techniques and dose escation.
VIRTUAL SIMUIATION;-A REALTY IN 016 SHFFFIELD.SPled1 C-Anthony',GBrown'
JJohnsot3, S Kingstone,J.Conway2, tRobinson , 'YCR. Dept. Clin Oncology, 2Physics Dept.
3Raiotherapy DepMt Weston Park Hosp. Whitham Rd, Sheffield S10
2SJ, UIK
Introduction: The combination of CT simulation, digitally
reconstructed radiographs and portal imaging has the potential to
reduce the need for a second conventional simulation when planning
simple orcomplex fields aangements Its role is so farunpoven. Aim: To report 1) the accuracy and feasibility of virtul simulation for
the palliatve treatent of lung cancer and in panned treatment of
laryngeal cancer. 2) the advantages and disavantages of Virtual
simulation aftera year ofuse.
Methods: 557 CT localisations were carried out during 1997 including
272 pelvic, 134 chest, 68 head and neck and 32 lymphoma patients.
Studies:
1) Assessment of the impact of respixation on target volume of
conventionally simulated lung cancer. palliation, showing no effect.
2) Assessment ofdifferent meth ofdefining fiducialsor anatomical
landmarks on conventional simulator films, Digitally Reconstrcted
Radiographs and Portal Images. This facilitates the registraon and
quantitative comparison of the setup achieved on conventional and
virul simulators, and the tetment machine using PIPS2 software.
Using these techniques we have found that it was pomsible to replicate a
conventionally simulated palliative lung poral to an accuracy of 1mm
(SD 2.5mm)m 10patients.
Virtual simulation of a 6 radical laryngeal carcinoma patients was
accurate to 1.8mm (SD 1.5mm).
Our current studies are looking at the impact the CT data has on field
size, symptomatic responseand toxicity in palliative lung radioderapy, and at the effect admnistrton ofintravenous contrast when scanning
has on the grosstumourvolume chosen by the cinician
When the planning CT anddiagnosticCTs of lymphoma patients were
compared the Gross Target Volume (GTV) was altered in 20% of
cases, usually because of disease progression between scans. A
technique for planning mantle and inverted Y radiotherapy will be
discused.
Head and neck cases have been successfully simulated.
Conclusions Themachine has rapidly beenaccepted by clinicians as a
tool for CT. On the basis of our early experience the scope for
improving treatmentacrrLacy and specificity iS great
5, = DYNAMIC CONTRAST ENHANCED MAGNETIC 015 RESONANCE SCANNING TO PREDICT OUTCOME
AFTER RADIOTHERAPY FOR HEAD & NECK CANCER
P J HoskinL MI Sauders. K GoodcdiK MEB PowelL J Taykr and H Baldele'.
Mourt VamonHospial, Northwood. Middx HA6 2RN, U.K.
Dynamic contras enhanced magnetic resonance imaging (DCEMR) uses
rapid acquisiion of sam images followmg intravenous a niati of
gadolinium with 30 images per scan slice being obained over a 219 second
period. This enables the uptake of gadolinium durig its disbution phase
into an area ofinterest to be monitored andsubsequently analysed.
This technique has been appLied to 13 patents with advanced head and neck
cancer with DCEMR performed before and on completon of a course of
accekrated radiotherapy. The scans have been analysed in terms of
maximum relative signal inensity (rSI) using the pre-contast signal intensity
as baseline, slope of the rSI against time curve and the time taken to reach
maximum rSI. The scan paameters have been related to tumour outcome
after radioerapy (RT).
Local tumour control was mversely related to the maxum rSI within a
region of mterest encompassmg the tumour on a post-RT scan but not on a
pre-RT scan, with durable tumour control bemg seen those tumours with an
rSI of< 8. The slope ofthe signal mitensity vers time curve on the pre-RT
scan sequence was also inversely related to control, the threshold value being
<7.5.
The resuls imply that tumours with a slow rate ofgadolinium uptake pror to
RT or reduced gadolinium uptake at the end ofRT are ose most sensitive to
reatent with accelerated radiation. Gadolinium uptake reflects both
vascularwity and vessel permeabity. Tumours which have high rates of
perfusion pre-RT and mta vascular networks post-RT are less likely to
respond to RT anddtese features predictloal failure.
This technique may be able to select dwse patients for elecfive salvage
surgery immediately after RT and also predid dtose patients likely to have
sustaned ocal contol with no furthertreatment.
STEREOTACTICALLY GUIDED CONFORMAL
'>17 RADIOTBERAPY FORMENINGIOMAS -
TECHNIQUE AND EARLY RESULTS.
F.R Saran, J. Perks, H Alheit, AP. Warrington, I. Rosenberg, C.
Beardmore, MiBrada, 'Department of Radiotherapy and Physics,
The Royal Marsden NHS Trust Hospital, Downs Road, Sutton,
Surrey SM2 5PT
P 1pose Descnibe the rationale, the technique and early results of
stereotacticaly guidled conformal radiotherapy (SCRT) for
Mateigi and metko From 7/93 to 11/97 24 patients (median
age: 56 yrs., range 28-72) with meningiomas were treated with
SCRT. Patients were treated stereotactically in a GTC frame to a
target volume (PTV) defined as gross tumour vohune (GTV) plus a
0.5-1 cm margin in 3D to doses of50-55 Gy/ 30-33#/ 6-6'/2 weeks,
using fixed conformal fields. Follow up was 1 - 36 months (median
7 months). Results were compared to a cohort of meningioma
patients treated with conventional radiotherapy (RT) (reported
previously).
ResasL: Treatment was delivered with 3 or 4 non-coplanar
conformal fixed fields using beams-eye-view (BEV) shaped lead
alloy blocks or a muli-leafcollimator, as the optimum stereotactic
technique to minimise the dose to normal brain. Median GTV was
21.7 cm3 (range: 4.4-183). Two patients experienced early side
effects. 1 -3 year progression free and overal suvial are 1000/o.
Condasion. SCRT is a feasible high precision technique
associaed with nminimal acute toxicity and tumour control
comparable to that seen with conventional RT. While it is possable
to show technical benefit of SCRT over conventionally delivered
RT, clinical advantage in terms of tumour control and long term
morbidity will need to be demonstrated in long term studies before
acceptng SCRT as the routne therapy for inoperable residual and
recurrent meningiomas8 Oral Presentatons: GENITO-URINARY CANCERS
018 INTERLEUKIN-2. INTERFERON-ALPHA
AND 5-FLUOROURACIL IN METASTATIC
RENAL CARCINOMA: Results of a modified
'Hannover' regimen
J.M.Abraham, D.Mort D.Morrey. M.D.Mason.
Velindre Hospital. Cardiff. UK
Encourazing results are reported' using the sequential combination of Interleukin-
2 (IL-2). Interferon -alpha (IFNN). and 5-Fluorouracil (5-FU). in the treatment of
metastatic renal carcinoma. In vies of the toxicitv and cost of this regimen. wse
embarked on a modification xshich omitted the lower dose IL-2 prescnrbed during
xseeks 2 and 3. The modified re6imen consisted of an 8 week course oftreatment.
During xseeks I and 4. 3 subcutaneous (sc) IFN at 6MU m was given once weekly.
combined with twice daily sc IL-2 at 10NML m- for 3 corsecutive davs In xweeks 2
and 3. sc IFN at 9MU m- was delhxered thnice xseekly. Finally. wxeeks 5 to 8
combined thn-ice x-eekly sc IFN at 9 MU m- uith a weekly bolus of IN 5-FU at
-,Oma m
patients xsere treated. The median age w%as 52 years (range 34 -73). 15
5.50o were identified as a good rnsk group. 8 2-9.- 00 as a moderate n'sk group
and 4 (14.800o as a poor n'sk group using a previously reported prognostic
classification X .ith a median follox up of 22 months (range 0.75-50). there haxe
been 3 1. 10o0 complete responses. 3 (11.1o) partial responses. 8 (29.60o) with
stable disease and 1'2 (4440o) with progressixe disease. 1 patient %%as not
exvaluable for response. The oxverall response rate was 22.200 xsith a median
duration of response of 14 months (range 3 - 22). In those with stable disease. the
median progression free duration xsas comparable at 12 months.
The median surxival in the responders w-as 20 months (range 13-28). 14 months
ranee -- O) in those xsith stable disease and 7 months (range 0.75-16) in the
disease progression group
In conclusion xse demonstrate that the orianal ILZ1FN 5FU re2ime can be
modified and is still actixe. Randomised control srudies xsould be needed to
demonstrate the fulI efficacy of this re2imen xhile comprehensixvely addressing
issues oftoXicitx and qualirx of life.
l I J. Atzpodien et al 1993 3 Eur.J.Cancer. Vol.29ASuppl.5 ppS6-S8.
2 ' Jones et al (1 993 Cancer Biotherap Vol 844) pp25>-288
2O-# THE EFFECT OF RECTAL ACTIV1TY ON
020 PROSTATE GLAND POSMON DURING CIN
MRI OF THE PELVIS: IMPLICATIONS FOR
RADIOTHERAPY PLANNING. V. S. Khooi, A R Padhuii2, J. Sudding2
J. E. Husband, M 0. Lac2, D. P. Dca[ eyl) . 'D q s of
Radi0theav, and 2CRC Clinical Magnetic Rserch Group, Roval Marsden
NHS Trust Sutton, Surrey SM2 5PT.
Aim: To detemine the effect of rctl activity onthe positon ofthe prostate
gland as u c d prostate nt during radical radiokhrapy will
impact on the probability of local control and may result in hige toxicit
with _nn srv irradiion ofsr ding normal issues.
Methods: 55 consecutv patints with prostate cancer were scanned in the
axial plane u repeated a Tl-weighted spoiled gradient echo sequene
(FLASH) every 10 seconds for 7 mins. 24 patents received bowel
reaxans before imaging. Pelvic img were analysed for the degree of
rectal dis for the mcidece, m and mnmber of rectal and
assocated prostate movI-ts.
Results: Overall real movements were see im 28 (51%) ofpatints; im 10
(42%) of those reiving bowl rdaxants and mi 18 (58/o) not rceiving
bowel reaxants. The incikde of real _ s correlaed with the
degree of rectal dission (p=0.0005). Prostate nxweO s wce soe in 16
(29%) patients and mi 9 (16%) patients, the mwore greater than 5
mm Overall, individual 86 real v s resulted mi 33 n o ofthe
prostate in the anteior-posteior direcio The magntde of these rectal
_ne,vum~its correlated well with the degree ofobserved prostate m ts
(p<O.00l).
Condusion: Cime MRI ofthe pelvis demostat signin rectal activity
which mfluaxes the prostate gland posit over a time period similar todtat
used for the ddevery of daiv radiodhrapy frcionated regimens. For
incred treatmnt accuracy, methods which allow for real time verifica
of dailv treat nt vohlunes are nede to am nt for internal organ
movuuamtsm finxividual patients
9< ^ PHOTODYNAMIC THERAPY FOR RECURRENT 019 PROSTATE CANCER AFTER RADIOTHERAPY: A
PILOT STUDY,TR Arokianathan. DE Whitelaw. WR
Lees. SS-C Chang. A Gillams. P Ripley, H Payne. M Emberton and SG Bo%n,
University College London Hospitals.
INTRODUCTION: Photodynamic therapy (PDT) involves activation
of a photosensitising drug with non-thermal light to produce localised
tissue necrosis. We report the early results of PDT for locally recurrent
prostate cancer after radiotherapy using the photosensitiser meso-
tetrahydroxyphenyl chlorin (mTHPC).
PATIENTS & METHODS: Ten patients aged 59-77 years (mean 68
years) with biopsy proven locally recurrent prostate cancer following
external beam radiotherapy had PDT as salvage therapy. Pre-treatment
serum prostate specific antigen (PSA) ranged from 2.2 to 38 ng/ml
(median 11 nglml). Patients were photosensitised with 0.15 mg/kg
mTHPC intravenously and kept in subdued lighting. Three days later
patients were catheterised urethrally and red light from a diode laser
(652 nm, 150-200 mW per fibre) was delivered via bare tip optical fibres
inserted transperineally into the prostate under trans-rectal ultrasound
(TRUS) or magnetic resonance imaging (MRI) guidance (up to 8 fibres
per patient; total energy 450 to 1600 J per patient). Contrast-enhanced
MRI and TRUS biopsies were performed two months post-treatment
Median follow up is 8 months (range 3-10 months).
RESULTS: Treatment was well tolerated. Post-treatment PSA levels
fell in S patients and 2 attained a PSA nadir <0.5 nglml. Post-treatment
biopsies showed necrosis and fibrosis in all patients with no evidence of
residual tumour in 4 men including those with PSA <0.5 ng/ml. MRI
revealed non-enhancing lesions at treatment sites which corresponded to
necrosis seen on biopsy. One patient developed incontinence; another
developed incontinence which has improved and impotence which has
not
CONCLUSIONS: PDT is acceptable to patients. Disease remission
can be achieved whilst complications compare favourably with other
salvage procedures. Refinements in drug-light dosimetry should
improve cancerclearance and reduce complications.
2I^Ss RANDOMIZED TRIAL OF HIGH DOSE CONFORMAL 021 RXDIOTHERAPY FOR PROSTATE CANCER-
INITIAL REPORT OF ACUTE TOXICITY' J V'ilson. \ Khoo. L Mle\er. \1
Bidmead. J W'arrineton. S Helher. J Gadd. R Huddart A Hor\sich. D
DearnaleN. The RoVal Marsden NHS Trust & Institute ofCancer Research.
Conformal radiotherap- (CRT) may permit safe dose escalation b! decreasing
the amount ofnormal tissues included in the treatment solume In 1995. w%e
commenced a prospective randomized trial ofhigh %s standard dose CRT in
localized prostate cancer. This planned analysis ofthe first 50 patients in each
group documents acute tox;icit during and following CRT to 3 months.
Eligible men w%ere considered suitable for radical CRT xsith TIb-T3 NO \10
prostate cancer. Initial androgen deprixation with LHRH agonist (and short
course cyproterone) w-as given for 3-6 months prior to CRT Patients %were
randomized to receive high dose (74G\ 7Fr 7.Ssk) CRT or standard dose
(64G- 32Fr 6.5\xk) CRT. All patients recei\ed 64G\ to a PTV including
prostate - seminal sessicles depending on the risk of insolsement) using a
marain of 1-1.5cm from GTV to PTV. High dose patients had an additional
l0Gy to the prostate alone wkith no added marain. Acute toxicits s%as
documented using the RTOG system.
Patient characteristics "ere balanced for the 2 groups. Oxerall: age (mean
67yr: range50-82).Tstage(21O%TI.48O0T2.310/T3).PSA(mean
17.5ng mL. range 1-145). grade ( 1900 W-D. 71oo M-D. 0°/o P-D). pre-CRT
symptoms (bladder 92% RTOG score=O. rectum 97% score=O).
No difference in maximum recorded acute bladder or rectal toxicit\ bet%seen
the 2 groups were found to 18 w%eeks offollow-up.
Max ToxicitN (% Datients w-ith RTOG score)
Bladder Rectum
0 1 32 4 0 l
4G ICRT(0o) 4 38 4 10 4 16 42 42
64Gx CRT (Io 24 38 26 1 0 24 30 40
p=0O (trend- p)j9 /trend
X e conclude that dose escalation % ith CRT in prostate cancer is not asso-
ciated xsith an increase in peak acute tox.icit. This study has no%% been
adopted as the first MRC Radiotherapy X ork-ing Party Trial (RT-O1 )and is
open for national recruitment.Oral Presentations: GENITO-URINARY CANCERS 9
REDUCTION OF RADIATION INDUCED
022 RECTAL BLEE ING USING RADICAL
CONFORMAL RADIOTHERAPY IN
PROSTATE CANCER: A RANDOMISED CONTROL TRIAL D. P.
Deamaley, V. Khoo, A. Norman, L. Meyer, A. Nahum, D. Tait, J.
Yarnold, A. Horwich. Institute of Cancer Research & Royal Marsden
NHS Trust, Sutton and London
Background: Radical radiotherapy (RT) is commonly used to treat
localised prostate cancer. Side-effects limit the dose that can be given.
but may relate to the volume of normal tissues irradiated. Conformal RT
CFRT by shaping the high dose volume to the prostate reduces the
amount of rectum and bladder treated. To evaluate this new technology
we have performed a randomised controlled trial comparing conformal
and conventional RT.
Methods: We recruited 225 men with prostate cancer who were
randomly assigned to treatment with radical RT, to our standard dose of
64 Gy in daily 2 Gy fractions, using either conformal or conventional
methods. The primary end-point was the development of late (>3
months after treatment) radiation induced complications which were
measured using the RTOG (Radiation Therapy and Oncology Group)
physician based scoring method. Disease control end-points were also
recorded.
Findings: After a minimum follow-up of 2 years CFRT produced a
significant reduction in the development of radiation induced proctitis
and bleeding (Grade >1, 37% versus 56% p=.0009; Grade .2, 5%
versus 15% p=.01). No significant differences were found in local or
biochemical disease control or overall survival.
Interpretation: Conformal techniques reduced the late radiation side-
effects of prostate cancer radiotherapy while maintaining similar efficacv
to conventional treatment methods.
024 THE LiE OF GERMLINF. GENETIC \LXRKERS IN THE t--kDROGE-\ RECEPTFOR GE_"-E TO IDEN-TIFi-
INDI\1DUXLS XT INCREASED RISK OF PROSTATE
C\NCER RELAPSE. RA Ecles--. AM Edwards-. MD Badzioch. R M\inrr. R Pack-. R
Harxudi, \ (Collns, A Aiden-lones-, S Do-w-. S Ostoffe, Kellk. R Sarer-. DOF
Easton GH Sainders-. DP Deamalev , ICR Surrev. S\2 5NG; -RN\Hs-T. London.
SW3 611; MD S-nderson Centni Texas, US-A, `TSclxdol of Pubbc Health. Houston. Texas.
USA;,CRC Genenic EpidemoioKs- Unit. Cmbrige. CBI 4R.N
One of de clinical problems n managin patients w-ith prostate cancer i; thut
ther 'Es a paucity of markers of earl relapse within each nrmour stage The
identifictimn of such marke would enable clinicians to determine which
patients could be offred w-atchful waiting versus radical derapy. \Xe have
analysed the (CAG)N- and (GGC)Q expressed polymorphic repeats in the
androgen receptor XAR' gene in tmlme DNA- in 178 UK Caucatian prostae
cancer patients and compared these repeat lengths with geographically matched
control Xt presentation 220%o of the patients had T1/2 dise, 37%0 had T3/4,
8%o had nodal ntastes and 330o had nmetatatic disease outside the peh-is. Xs
expected, the disease-free sun-ival was sigmficandv improved in stages TI-T4
ves-us node-positive/datrant mewtatic disease Up< 0.001) and with decreasing
T-stge. D\A from blood lymphocytes from 178 prostate cacer patients -and
178 geographicallv matched controls wAs submifted to radiolabelled PCR and
AR repeat length detennied by ninnmg the PCR products on polacrvlamide
gels with known size markers. Long >21 CAG repets sigficandtl increased
as dte diease sta increased 'X: trnd = 7-3, p=1).007'J. For GGC repeat lenth,
there was no evidence of anv stage-associated trend. Patients with TI-T4 dise2se
had a statistically sgnificant longer relaps-efree pernod of, on averAge, 101
months ifdteir GCGC repet length -as <16 repeats 49 patients relapsed out of
108; p<0.002). This period was 23 tinses longer than those patients w-idi >16
repeats with the same dinical stge. The same effect was observed if the patients
were partitioned bv age '<70 v. >70 years) or were grouped as organ-confined
Il/T2) or escaped T3/T4. These data suggest that the use of a grnrline
polymorphic marker nav be a usefhl -ew prognostic marker for the progression
of prostate cancer within each clinical T stage and may be able to detenine
w-hich patients should be offered earier radial treatment for localised disease
PREIM4INARY RESULTS OF AN NRC TRIAL OF
023 PAILITATIVE RADIOTHERAPY IN ADVANCED BLADDER
CANCER. J J Bolger, G Duchesne,
G Griffiths & B Uscinska on behalf of NRC Bladder Cancer
Working Party, NRC Cancer Trials Office, 5 Shaftesbury
Road, Cabridge, CB2 2BW, UK
A multi-centre, randcmilsed crcnr e r-ae - cmcar1nz
efficacy and side effects cf -wc pal'-at_ve raditnrpy
schedules !35 -y in 10 fracti4ns and 2' 2 y n 3 frc-.- -'r
i-n patients with advanced bladder cancer was ccnd l-eto.
Eligible patients had symptomat_ , h1stc1-_acil7y prcven
invasive bladder cancer, were considered unsu'tatle f^r
radical radictherapy or chem therapy a-nd had a 5lfe
expectancy of at least three mcnths. UTrinary and btwet
symptoms were assessed at pre-treatment, end ^f treatmenr
and at three months. From Ncvember 1992 t^ Ncvemter 19007
a tctal of 500 patients were entereo ty 2C centres. 352
patients have d-ied. Ihere was f-unrd tcte nc evidence cf
a difference i-n survival betweer rad-irtherapy scheduleS
"Hazard ratic=1.04 95% CI 0.84-1.28 p-value=:.72 . A
total of 428 patients had symptom data at b¢th pre-
treatment and at end of treatment assessments and 2f-7 a-
toth pre-treatment and 3 month assessments. Ihere was n^
evidence that the change of symptoms between pre-
treatment and at end of treatment or 3 mont:r assessmen,
were differert between tne twc rat cthera-y sche-'d7 es.
Altncugh thIs is the largest troal conducoeo cf oall_ai-'-e
therapy in bladder cancer, m dest differences cannr te
reliably excluded. Nevertheless, from current data we
conclude that there is nc evidence of a difference
between the two palliative radi therapy schedules _r terms
of survival and symptom palliatcn.
IMMUINOTHERAPY FOR PROSTATE CANCER - N
025 VITRO STUDIES PJ Atherton. M Gilligan. LS Young.
PF Searle. AB Rickinson. ND James. CRC Institute for
Cancer Studies. University of Binningham. Birrningham B 15 2TA
Aim: To evaluate the ability of prostate cancer cells in culture to act as
targets for cell rmediated immune responses by studying antigen
processing and presentation in prostate cancer cells in vitro.
Methods: The prostate cancer cell lines PC3. DU145. LNCaP. TSU-
Prl. JCAI were studied with LCLs as positive controls for antigen
processing. Expression of class 1 and class 2 MHC antigens was
examined in all cell types. Antigen processing in 2 cell lines. one
positive and one negative for class 1 MIC expression was examined in
detail in functional assays.
Results: Expression of class 2 MHC antigens was down regulated in
all the prostate cancer lines studied. Expression of class I MHC
antigens was preserved in all of the prostate cancer cell lines except for
LNCaP which was down regulated to low levels, was not inducible
with interferon but was partially inducible with TNFa- Expression of
the antigen transporter protein TAP1 was down regulated in the LNCaP
cells. Functional assays either transfecting single EBV-derived genes
or adding the corresponding processed peptide sequence were carried
out with appropriate specific cytotoxic T lymphocytes. The class 1
positive cell line TSU-Prl was able to process the EBV antigen
appropriately and was lysed in a specific fashion. In contrast, the
LNCaP cells were unable to process a TAP-independent antigen even
with the simultaneous transfection of the appropriate HLA haplotype
showing that the antigen processing defect in these cells was TAP
independent.
Conclusions: Some prostate cancer cell lines have intact machiner) for
the appropriate presentation and processing of antigen although other
cell lines such as LNCaP have clear functional deficiencies that cannot
be easily overcome. The data does show that at least in some cases and
an immunotherapeutic approach to prostate cancer may be feasible.10 Oral Presenta6ons: GEN[TO-URINARY CANCERS
LONG TERM FOLLOW-UP AFTER
026 RADIOTHERAPY FOR MUSCLE-INVASIVE
BLADDER CANCER
PW\ Cooke. DMA Wallace , j Iunn', S Bathers'. T Latief2. ND James'.
'CRC Institute for Cancer Studies & 2Queen Elizabeth Hospital.
Birmingham.
Aim: Muscle-invasive bladder cancer carries a poor prognosis with a
five year survival rate of less than 40%. Debate remains as to the
optimal form of treatment between primary cystectomy and
radiotherapy with salvage surgery, with or without chemotherapy. We
report the long-term outcome of patients treated in the West Midlands
neoadjuvant study ofcisplatinum and radiotherapy.
Methods: Patients with biopsy proven muscle invasive bladder cancer
of category T2 - T4a NX MO, and WHO performance status 0-2 were
entered into a prospective randomised study comparing radiotherapy
versus radiotherapy with ncoadjuvant cisplatinum between June 1984
and June 1988. Follow-up was by 3 monthly cystoscopy in the first
year. 6 monthly the next 2 years and yearly thereafter. Salvage surgery
wsas perfonned at the discretion ofthe participating clinician.
Results: Median follow-up to 1997 was 11 years with a minimum of 9
vears. at which time 29 patients (18%) were still alive. Mean age of
patients was 65 years (SD 6.7 years) The median survival was 24
months. There was no difference in survival between the 2 treatment
groups (p=0.77). Overall cystectomy rate was 24% (radiotherapy alone
20e. combined therapy 28%; p=0.24). Median time to cystectomy was
12 months, range 56 days to 10 years.
Conclusions: Salvage cystectomy is necessary in a quarter ofpatients
after radiotherapy and this can be needed up to 10 years after treatment.
Clinicians should be aware of this and patients should be fully
counselled about the prolonged need for surveillance and the persisting
risk of salvage surgery when deciding between primary cystectomy and
radiotherapy. Ways of improving the local control achieved with
radiotherapy are urgently needed.Oral Presentatons: CHEMOTHERAPY & PHARMACOLOGY 11
27s A PILOT PHARMACOKINETIC STUDY OF 0 AMSALOG (CI-921) ADMINISTERED ORALLY
ON A FIVE DAY SCHEDULE
D. Fyfe', F. Reynaud2, J. White', K. Claytm', L. Masm', C. Garner
P. J. Woll', I. JudSc2, and J. CarnMdial'. 'CRC Dept of Cnimcal
Oncology, Nntmgham City Hospital, N htingham U-K 2ICR, Royal
Marsdn Hospital, Lkmd, U.K. ;CRC, Regmts Park, Ladkx, U.K.
Introduction: Amsalog is a derivative of 9-aminoacridine. Phase I
studies using intravenous Amsalog showed the dose limig toxicity
(DLT to be phlebitis and myelosuppression Phase II studies using 200
mg/m i v daily for 5 days showed evidence of activity in large cell
hng and prostate cancers Amsalog is active orally: pre-clincal studies
showed 26% bioavailabilty in fed rabbits, 69/oin fasted In view of
this, a clinical study oforal bioavailability ofAmsalog was performed
Patients and Methods: 19 patients with refracory malignancies were
treated in 4 cohorts Treatment was repeated every 3 weeks For the
first and second cycles, Amsalog was administered intravenously at
200 mg/M2 on day 1, then orally on days 2,4,5, and 6 The first oral
dose was 200 mg/M2 Pharnacokinetic studies were performed to
assess bioavailabiity Dose escalation was based on oral bioavailability
and toxicity In the absence of DLT, and ifplasma drug levels after
oral ainsraion were below those obtaied itravenously, there was
intra-patient dose escalation of up to 100%/ for the second cycle
Patients were then given Amsalog oraily on days 1 to 5 for subsequent
cycles. Ifthe higher dose was tolerated, the next cohort was treated at
this level initially, with a further intra-patient dose escalation for the
next cycles
Results: Mean oral bioavailability was 28.4% (median 27 7, range
13 8-53 4%) Toxicities included mild lethargy and nausea
Conclusion: Amsalog is well tolerated orally on a 5 day schedule at
doses up to 800 mg/M2
Biodistribution and pharmacokinetics 1111n-DTPA-
029 labelled Stealth liposomes(IDLSL) in patients with
solid cancers. Hamngton Ka Abra R>. Uster Pt.
Stewart Sa. ICRF Oncology Unit, Hammersmith Hospital, UKa
SEQUUS Pharmaceuticals Inc.. USAb.
Purpose: To investigate the biodistribution and pharmacokinetics of
IDLSL in patients with advanced solid cancers as a means of assessinz
their potential role as a vehicle for the delivery of cytotoxic drugs and
radiosensitising agents.
Patients and Methods: 17 patients (5 breast ca, 5 head and neck ca.
4 lung ca, 2 glioma. 1 cervix ca) received 65-107 MBq of IDLSL by
intravenous infusion. Blood samples and whole body gamma camera
images were taken at 0.5, 4, 24, 48, 72, 96 and 240 hours and
sequential 24 hour urine collections were performed for the first 96
hours. SPECT imaging of regions of interest was carred out as
indicated. Liposome uptake in tumour and nor-mal organs was estimated
from regions of interest on the gamma camera images. In a separate
study, 2 patients undergoing excision ofhead and neck cancers received
27 MBq of IDLSL 48 hrs before surgery. Samples of tumour and
normal tissues were obtained at operation.
Results:
0.5 k 4 k 24 k 48 b 72 h 240 i
Blood 950±11.8 85.3±9-5 70.7±9.2 | 55.5+93 | 46.3±95 4.95.1i
Plasma 100 9-13.6 90.8±13.0 591±12.1i 49.0+11.9 39 1±11.1 4.9±5.4
The excretion half-life (tlp) ofIDLSL was 76.1 h. Median cumulative
urinary excretion of 11 lIn over 96 hours was 19.5 (range 3.5-28.4) %
of the injected dose (%ID). Positive tumour images were obtained in
15/17 studies (4/5 breast, 5/5 head & neck, 3/4 bronchus, 2/2 glioma,
1/1 cervix cancer). Tumour liposome uptake estimated from regions of
interest on the whole body gamma camera images showed considerable
heterogeneity, both between different tumour types and between
tumours of the same histological type. Total tumour uptake ranged
between 0.5-3.5 %ID, with peak uptake at 72 hrs (mean 1.4±0.9 %ID).
Peak normal organ uptakes (%9ID) were as follows: liver (4 hrs)
11.7±1.9, spleen (72 hrs) 5.1±2.2, lung (0.5 hrs) 5.6±1.4, kidneys
1.6±0.8. In the 2 patients undergoing surgery, tumour uptake was 8.8
and 15.0 %ID/kg, respectively. Tumouruptake exceeded that in normal
mucosa by a mean ratio of 2.4:1
Conclusions: This study confirms that Stealth liposomes effectively
target a range of common solid cancers.
028 APOPTOTIC INDEX AS A PROGNOSTIC
FACTOR IN A TRIAL OF PRINIMARY MEDICAL
THERXPY FOR CARCI-NOMA OF THE BREAST R Gregorv. P
Ellis. T Pow-les, NI Dow,sett Royal Iarsden Hospital. Sutton- UK
NMethods Apoptotic index (AX) >-as determined
immunohistochemicallv bv ISEL (In-Situ-End-Labelling) on paraffin
embedded sections from 21 1 patients randomised in a trial ofprimary
medical therapy (PAlT) at the Royal Alarsden Hospital In this trial.
patients w-ere randomised to receive either 3 months of
chemoendocrine therapy (mitoxantrone 11mg m2. methotrexate
35mgnm2 to a maximum of 50mg q21 and tamoxifen 20ma od.
MLNIT) prior to surgerv - neoadjuvant group (NG). or
chemoendocrine therap- in the adjuxant setting - adjus-ant group
(AG) Therefore. halfofthe tumours examined in this studv had been
exposed to 3 months ofchemoendocrine therapy
Results Al was available on tumours from 96 patients in the N-G and
115 patients in the AG In the NG the median Al A-as 0 17 (0-2.6)
compared to a median of 0 35 (0-3 8) in the AG.i this difference is
statistically significant p=0 0004 A high Al post treatment (ie
>0-17) w-as associated wxith a poor response to NIMIT treatment.
p=0 004 and this group of patients also had a siunificantly wxorse
DFS. p=0 03 Al did not predict for DFS in the group as a >-hole. or
in the adjuvant arm
Conclusion A-I would appear to carrv both prognostic and predictive
povwer in patients receiving neoadjuvant chemoendocrine therapy for
pnmarx carcinoma of the breast In addition. although >-e hax-e no
pre-treatment samples available on these patients XA u-ould appear to
be reduced bv \MIT treatment
^ CHANGES IN HUMAN TUMIOUR PERFUSION AFTER 0ov DNMXAA TREATMENT. IONITORED BY DYNA-.vNIIC
GD-DTPA ENHANCED MItR.SMI. Galbraith'. N J Tay-lor-. G.
Rusnn . H Baddelevy. 'Cancer Treatment Centre and.2Paul Strickland Scanner Centre.
Mount ernon HospitaLNorthwxood_ Middx. HA6 2RN. UK
Background: Dimethylxanthenone acetic acid (DMXA.A). a novel
tumour vasculartargetingagent causes a reduction in tumour perfusion
leading to response and haemorrhagic necrosis in animal tumours.
Objective: To assess x-hether tumourperfusion is affected in patients
participating in the Phase 1 trial ofDNMXAA.
Methods: 3 patients were scanned pre-treatment, 4 hrs and 24 hrs after
the first infusion, and after 6 weekly infusions of DMXAA (500mgm-
patient 1,650mg m- -patients 2 and 3). 30dymamic images were obtained
at 12.8s intervals prior to. dunrng and after intravenous injection of
Gadolinium-DTPA. The sequential images w-ere analysed for each pixel
to generate parameter images ofmaximumsignal intensity time uradient
and enhancement. Both these parameters have been used as measures of
perfusion. Regions ofinterest (ROIs) were defined for each dymamic
series of scans to encompass the tumour and also for nearby muscle. The
difference between the means for the above parameters wxithin these ROIs
pre and post treatment wxas compared using a twxo-tailed t test.
Results:The mean gradient maximum for the first 2 patielt-s tumours fell
bv 22°' and 300, respectively (p<0.01) bx% 24hrs and bx 37'0 and 280,
(p<O.Ol) by 6 xxeeks. but x-as unchanged inthe third patient. The mean
enhancement wxas unchanged in the first patient. but reduced by 16%i and
25',/0 respecti'vely (p<0.01) in the next 2 patients. Therex-ere no
significant changes in maximum gradient or enhancement in underlvins
muscle-The parameter images illustrated that the changes in blood flowx
u-ere heterogeneous within the tumours. All 3 patients experienced pain
in the tumour site after each infusion.
Conclusions:The documented changes in tumour blood flowx demonstrate
abiological effect ofDMXAA in humans, and provide exidence
supporting the concept oftumour xascular targeting. Further patients are
being recruited for blood flowx imaging.12 Oral Presentations: CHEMOTHERAPY & PHARMACOLOGY
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HIGH DOSE CHEMOTHERAPY (HDCT) WITH PBSC
033 SUPPORT FOR EITHER POOR PROGNOSIS OR
RELAPSED NON-SEMINOMATOUS GERM CELL
TUMOURS (NSGCT)
Wilkinso P M, Decatris M, Heron J, Morgenstem G and Welch R S.
Christie Hospital, Depts of Clin Oncology and Haematology, Manchester.
Whnistthere s gwneral agreement as to the teatment of good prognosts NSGCT,
the treatment of advanced and relapsed dsease remains a diallenge. The
efficacy of HDCT with PBSC support was evaluated in 16 pts with advanced
disease (as defined by the MRC prognostc analysis) and in 8 pts who had
relapsed following standard terapy. All pts recerved 3 or4 cycles of induction
terapy before receving HDCT (Etopside 450mgfM2, Cycopophanide
35mgJkg and carboplatin AUC*30). Pts were harvested after the first cycle; the
CD34 count had to be >1x106/kg and GM-CFC >5xW/kg to allow HDCT to
proceed.
Results
N Age Prinary
Gonad Other
Poorprognosis 16 29(15-45) 12 4
Relapsed 8 28(1545) 5 3
Duration of Days in Outcome
Neutropenia Hospital CR
92(9-12) 22(17-50) 12(75%)
9.4(5-11) 21.5(13-36) 4(50%)
Whilst the majority of pts became febrile during the period of neutropenia there
was no ifethreatening toxFity and no toxic deaths were rcored. The response
in de-novo pts was 75% falling to 50% in relapsed pts.
HDCT is a safe treatmt option for newly diagosed pts; its roe in relapsed
disease requires furter studies.
PHARMACOKINETIC (PK) INTERACTION BETWEEN
032 5-FLUOROURACIL (5-FU) AND OXAUPLATIN (L- OHP). D Papamchael, S P Joel, 'M T Seymour, 'F
Richards, M Bowerbank, M L Slevin. Departments of Medical Oncology at
StBartholomevs Hospital, London and YCookrxkge Hospital, Leeds, UK
Background' The combination of 5-FU and L-OHP has exhibited
clinical synergistic activity. We searched for a possible PK interaction
to explain this synergy. Patients/Methods: In the context of a
randomized phase 11-Ill clinical trial comparing 5-FUlLeucovorin (LV)
with or without L-OHP, 16 patients with advanced/metastatic
colorectal cancer- 8 in each arm -have been studied to date. The
regimen comprsed LV (200mg/rn2) i.v. infusion over 2 hours
immediately followed by 5-FU (400mg/m2) iv bolus then 5-FU
(600mg/m2) by iv infusion over 22 hours, all repeated on day 2 and
given fortnightly; L-OHP was given as a 2 hour infusion together with
LV, day 1. PK sampling was performed on day 1 of the 1 cycle, with
samples taken at time 0 (pre-bolus), 5, 10, 15, 20, 30, 45 minutes
and 1, 1.5, 2, 2.5, 3, 6 and 22 hours. Samples were immediately
cold-spun and the plasma stored at -40°C. 5-FU was analysed by
reverse phase HPLC. Kinetic data were fitted to a one compartment
model with two elimination routes, one linear and the other non-
linear, the latter with Kffi fixed at 15 uM representing the principle
catabolic pathway via dihydropyrimidine dehydrogenase. For each
patient the distributon volume (VJ), maximum non-linear elimination
rate (V,,) and linear elimination rate (k.~,,.) were derived using a non-
linear iterative procedure. AUCz22 was determined using a
trapezoidal method. Results: 5-FU PK parameters with and without
L-OHP are shown in the table (mean ± SD).
Vd L) V,,, (Urnhr') kw.;,) AUC (uMhrN1)
5-FU alone 20.8±9.3 362±215 3.5±0.9 90.3+28.6
p (Mann-Whitt.) 0.81 0.48 0.05 0.05
5-FU/L-OHP 22.6±8.7 274±199 5.9±3.1 61.3±17.0
Conclusions: L-OHP as used in this regimen, significantly affects 5-
FU PK, seen as reduced AUC and increased linear elimination but
not non-linear clearance. We hypothesise that L-OHP enhances the
anabolic pathway for 5-FU.
POSSIBLE ADVERSE EFFECTS OF
034 CURATIVE CHEMOTHERAPY ON BONE
MASS IN MEN: USE OF BONE
ULTRASOUND TO EVALUATE BONEARCHITECTURE
J. Zekri and R.E Coleman, YCR Department of Clinical Oncology,
Weston Park Hospital, Sheffield.
Chemotherapy is known to have long-tertn adverse effects on
skeletal health, particularly in women due to effects on endocrine
function with induction of premature ovarian failure. However, little
is known about the possible direct effects of cytotoxic drugs on bone
cell function and consequent effects on bonc mass and structural
integrity.
We have screened 114 men on long term follow-up after
combination chemotherapy for testicular tumours (n=42), lymphoma
(n=67) and other tumours (n=5) using bone ultrasound attenuation
(BUA) measured at the calcaneus; a quick, safe and simple method for
evaluaing bone mass which has been shown to correlate well with the
risk of osteoporotic hip fracture. Three measurements of BUA
measured in the non dominant foot were averaged and compared to
both a large database ofage-matched normal men and 49 age-matched
cancer controls who had not received chemotherapy. 99 men had
received 'standard dose' chemotherapy and 15 had also received 'high
dose' myeloablative chemotherapy supported by autologous stem cell
rescue.
25/114 (22%) men had BUA T scores >2 S.D. below the age
matched mean for normal subjects compared with only 5/49 cancer
controls (10%). After adjustment for age, exercise and steroid intake
by multiple linear regression, we found a small adverse effect of
chemotherapy on BUA. This was most marked and reached statistical
significance in men under the age of 30 (n=35; p=0.03 1), particularly
after high dose chemotherapy (n=6; p=0.029). Men aged 30-50
showed the least reduction in BUA from normal; thiscorresponds with
the age around the attainment of peak bone mass and before the phase
ofnatural bone loss.
These data suggest that chemotherapy may have direct non-
endocrine mediated effects on bone mass. Further investigation,
particularly in young men using bone densitometrv and biochemical
assessment of bone metabolism is indicated to assess the risk of
chemotherapy-induced osteoporosis.Oral Presenatbons: CHEMOTHERAPY & PHARMACOLOGY 13
35= DOES CENTRAL NERVOUS SYSTEM 0 CHEMOPROPHYLAXIS HAVE A ROLE IN THE
MANAGEMENT OF GESTATIONAL
TROPHOBLASTIC DISEASE? A M Gillespiel, N Siddiqw2, R E
Colemanland B W Hancockl. ITrophoblastic Disease Centre,
Yorkshire Cancer Research Dept Clinical Oncology, Weston Park
Hospital, Sheffield, UK 2Dept Obstetrics & Gynaecology, Southern
General Hsopital, Glasgow, UK
The role of prophylactic chemotherapy for cerebral micrometastatic
disease in persistent trophoblastic disease (P`TD) is unclear. The aim of
this project was to evaluate the outcome of patients with lung
metastases, who at some specialist centres would be deemed to be at
high risk of developing central nervous system (CNS) metastases and
receive prophylactic intathecal (IT) chemotherapy. At our centre IT
theapy is reserved for those patients with confirmed CNS involvement
as determined by imaging or a high (>1:60) cerebrospinal fluid to
serum hCG ratio.
Methods: All patients with gestational tiophblastic disease (GTD)
registered from 1987-1996 were included in thisretrspective analysis.
195 patients with PI'D) were treated during this time period, median
age 27 years (range 16-49 years). The extentofpulmonary metastases
was determined by imaging investigations.
Results: 69 patients with pulmonary metastases were identified- 51
patients were classified low risk and 18 patients high risk according to
the modified Charing Cross criteria 66/69 patients have successfully
completed their tratment (median follow-W 62 months, range 14-128
months). Two patients had established cerebral metastases, one being
successfully teated and the other dying despite multiple therapeutic
interventions. One other patient developed a CNS metastasis dunrng
treatment compromised by patient non-compliance. Follow-up is
ongonmg
Conclusion: Restriction of IT treatment to those patients with
established cerebral metastases appears to be safe and effective, and
the use of CNS chemoprophylaxis based on the presence of multiple
pulmonary metastases is unnecessary.14 Oral Presentatons: BREAST CANCER 1 (see also pages 24-25)
Ote ~~IS CLIN'ICA~L UN-CERTATNTY SUFfFCIEN`TkNi\ON'GST BREAST
36 CANCER SURGEONS FOR THE IMPLEMENTATION OF AT
RDONDISED TRIAL OF HRTIN BREASTCANCERPATTEN-TS"
J Nlarsden I JM Bliss IDept ofSurers. St Heliers Hospital. Swnrre UK
and -Secton ofEpidemiolop. Institute ofCancer Rescxch. Suoton. ILK
Introduction:Breast cancer patients experience oestrogen deficiencv
symptoms as a result of natural menopause or as side-effects of
adjuvant therapy (reported incidence of 66%). Randomised trials
assessing HRT in such patients are urgently needed and a UK trial is
planned. We wanted to determine how breast cancer surgeons'
currently treated symptomatic patients and their views on HRT.
Method:One page postal questionnaire sent to 250 designated breast
cancer surgeons (BASO Breast Group listing).
Results:Response rate was 49%(122/250). Most surgeons who
responded, 880o(107/122). treated more than 50 patients/year.
Median estimated proportion of patients suffering oestrogen
deficiency sy'mptoms was 25% (range 2%lO-100%) and was not
influenced by number of breast cancer patients/year. 770%o(94/122)
had preViously prescribed HRT. usually for relief of sexere
symptoms when altematives had been ineffective. only 1 10o(14/122)
stating that ER status would affect their decision. In answer to the
question Do you believe that HRT may have a role in breast cancer
recurrenceT. 520o(64/122) said 'yes'. 19%(23/122) said 'no' and
240o(29/122) %NTote that the' 'didn't know'. HRT alternatives
considered 'safe' included low dose progestins and topical
oestrogens. 210 (26 122) did not prescribe altematives or refer
patients for gymaecological advice. A randomised trial was felt to be
ethical by 740%o(90/122) but some envisaged difficulties with
organisation and questioned the level ofinterest from patients.
Conclusions:The incidence of oestrogen deficiency symptoms in
breast cancer patients is underestimated and use of HRT and
alternative therapies is not evidence based. There is uncertaintv over
the risks of HRT and it is encouraging that the majority of surgeons
believe a randomised trial to be ethical.
038 DY'NAMIC MAGNETIC RESONANCE
MAMMOGRAPHY ALONE IS SUPERIOR TO
TRIPLE ASSESSMENT IN SYMPTOMATIC
BREAST DISEASE
S.Chatte jee. P.J.Drew. J.N.Fox. P.J.Carelton. L.Tumbull. J.Read.
J.R.T.Monson. M.J.Kerin. Academic Surgical Unit. Castle Hill
Hospital. Hull
The accepted gold standard oftriple assessment ofbreast lesions
i.e. clinical examination. fine needle aspiration cytology (FNA) and
mammography does not alwsays establish a diagnosis and surgical
biopsy is therefore required. Contrast enhanced dynamic magnetic
resonance mammography (MIRM) represents an emerging
alternative diagnostic modality. The aim ofthis study vwas to
compare the diagnostic accuracy ofMR.M and standard triple
assessment in the evaluation ofsymptomatic breast lesions.
Tw-o hundred and eighty three symptomatic patients (median age
51. range 20-80) were recruited. T.he 112 patients who did not
undergo operation have been followed up clinically and
radiologically for a for a median of 20 months (IQR 18-24
months). For detection of malignancy u-ere: clinical examination
84.730No. mammographv 86.26%. FNA 80.3%. triple assessment
99.230,o and MRM 99.23%. Histologically confirmed multifocal
disease was detected pre-operatively in 40 patients by MIR.M but
only 9 (22.50o) on mammography. The specificity for the diagnosis
of benign disease was: cliriical examination 83.11%. ultrasound
88.88%. mammography 86.3600. FNA 95.0%. triple assessment
77.270o ar.d MfR-M 98.70o.
\MR.M is far superior to the traditional triple assessment for the
exaluation of symptomatic breast disease. and thus facilitates a
significant reduction in the biopsy rate to rule out cancer.
NEURAL NETWORKS ARE SUPERIOR TO THE
037 TRADITIONAL PROGNOSTIC INDICES FOR BREAST
CANCER PATIENTS, PJ.Drew, P.Magee, L.Bottaci,
M.Menon. K Heer. G.S.Duthie, J.N.Fox. P.J Carleton, J.RT.Monson, MJ.Kerin The
University ofHull Academic Surgical Unit Castle Hill Hospital. Hull HU16 5JQ
AXn artificial neural networks (ANN) is a form ofartificial intelligence
that is able to learn non-linear causal relationships between data sets
and therefore has a theoretical advantage over the traditional linear
statistical methods used in the construction ofprognostic indices. We
therefore compared the ability ofANN's to predict outcome in breast
cancer with the established Nottingham prognostic index (NPI).
Data on 460 patients collected retrospectively on the standard BASO
database was used to train and validate the ANN. As with the
Nottingham prognostic index the size. grade and lymph node status
were used as the input nodes with a variable number ofneurones
utilised in the hidden layer and a simple positive/negative output
neurone. The ANN was trained to predict death at one year on 435
patients and then validated on data from 25 randomly' selected patients
which had been removed prior to training. The ANN's predictions
w-ere then compared to the patients' Nottingham prognostic group.
The A.NN achieved an overall accuracy of84% (95% C.I.0.70-0.98)
for the prediction ofdeath at one year. The positive predictive value
ofthe network's predictions was 1.0 and the negative predictive value
0.83. In contrast. ofthe patients in the same validation set. 38% of
patients in the moderate-risk group were dead at one year as compared
to only 33% ofpatients in the high-risk group.
Artificial Neural Networks are able to predict outcome for breast
cancer patients with greater accuracy than the traditional prognostic
indices and particularly for the majority ofpatients in the "moderate"
risk group.
RECURRENT BREAST CANCER DETECTED
039 USING DOPPLER ULTRASOUND, MRI AND
MAMMOGRAPHY. E. C. Whipp, C. Devrell, N Vaidya, M
Halfiwel, P. Goddard, C. Wakeley, E. Kutt, J. Brennan and *P
Barrett-Lee. United Bristol Healthcare Trust, Bristol BSI 6SY, UK
*VelireHospital, CardifflCF4 7XL, UK
Objective: To establish the value of m oaphy, Doppler
ultrasound and g n enhanced MRI for the detection ofrearrent
breast cancer m the prevously irradiated breast.
Methods: 104 patients with breast induration following adjuvant or
neo-adjuvant radiotheapy following wide local excison, hormone
and/or chemotherapy and radiotherapy were investigated with
n Dop1 ulasound and MRI with aou
contrast. Fme needle aspirates were performed m anysuspiciu case.
Results:. In the whole group there have been 20 proven reairence.
The mean follow-up period was 30 months (range 18 - 48 months).
The sensiivi rates were: MR[ 88/!.; Doppklr 80K!.;
4r/.; the specificities were 8r/, 76% and 85% respecively. The false
negative reports (MRI 2, Doppler 4 and 7) overlapped
so that every reacrrence was detected by at least one modality. i.e.
100%! when using both MRI and Doppler uhrasound.
Condusions: Both ultrasound and MRI detect the neovascuature of
rectrrent breast cancer, with MRI being more sensitive and more
specific. Mammography is relatively insensitive to malignant changes
in the post-operaive and treated breast. These patients were all at
inceased risk of local recurence making a 100"!o sensitve detecton
important in their managementOral Presentations: BREAST CANCER 1 (see also pages 24-25) 15
AO t ^ A RANDOMISED STUDY COMPARING 3-WEEKLY 4U EPIRUBICIN, CYCLOPHOSPHAMIDE AND
CONTINUOUS INFUSION 5-FU (ECF) TO A 2-
WEEKLY SCHEDULE WITH G-CSF IN ADVANCED BREAST CANCER,
R-H De Boer, T.G Eisen, P-A Ellis, S.R.D Johnston, G Walsh, and I.E Smith.
Dept ofMedicine, Royal Marsden NHS Trust, Fulham Rd, London, SW3.
Granukocyte-Colony Stimulating Factor (G-CSF) allows cycles ofconventional
bolus chemotherapy to be accelerated witi reduction in treatment time and a
boost m dose-intensity'. Theoretically, the same approach could be hazardous
with infusional chemotherapy, since G-CSF-stinulated neurophil proliferation
would be occuring in the face ofcontinuous S-phase active 5-FU. We therefore
carried out aphase II nndomised study compaig stanrd 3-weekly infusional
ECF with an accekrated 2-weekly schedule with G-CSF support, in patients with
advanced breast cancer. Patients received day I epirubicin 60mg/M2 and
cyclophosphamide 600mg/M2 each cycle, and 5-FU 200Mg/m2/day continuous
infusion throughout G-CSF 300mcg/day s/c (day 10-12), was given each
accekrated cycle. 21 paients were randomised (10 accelerated). 6 pat s in the
standard arm and I patient m the accelerated arm were previously untreated.
Results showed that there were no treatment delays secondary to inadequate
neutohil orplatelet recovery, and the median dat I nutophil counts for each
cycle were higher in the accelerated arm [5.0 x 10 /L (range 3.0-9.0) vs 3.0 x
109JL (range 23-43)]. Neutropnic fever occurred in 3/11 patients (3-weekly) vs
4110 (2-weekly), grade 3 stomatitis in 2,'11 vs 3/10, and grade 3 planter-palmar
erythena in I patient in each. 88o ofthe planned standard chemotherapy cycles
and 85% ofthe planned accelerated cycles were given. The planned and given
dose intensity was as shown:
Cydoph| Epirubicin 5FU
3W Planned 20@rsm-lwk =1.0 20mg/mZlwk =1.0 0 1400nEwk
Dose Intensity =1.0
3W Given Dl 0.99 0.99 0.95
2W Planned DI 300mg/m2/wk = 1.5 30mg/m2twk =1.5 1400mg/m2/wk
=1.0
2W Given Dl 1.47 1.47 0.97
We conclude that accelerated infusional ECF with G-CSF support is feasible and
well tolerated with rapid haematological recovery. An overall 30%/ increase in
dose intensity is acheived, while treatment time is reduced by 33%.
'Bisse D, Jo&dlD, HdmeD A-N. Habcsha, T., Kave,S.B, Evans, D, Williams, Mi. and
C.anc1, PA. (1995) Phasc Iszut) ofaccelerated FEC with G-CSF (Lrnograstim) supWt BrJ Ca
71, 1279-1282
042 ASSESSMENT OFDIAGNOSTIC
STEREOTACTIC EXCISION OF
TMAMMOGRAPHIC ABNORMALITIES
M Menon PJ Dresw, MJ Imrie, JN Fox, PJ Carleton, JRT Monson, MJ Kerin
TheUniversity ofHull Academic Surgical Unit,Castle Hill Hosp., Hull
ALM: The drawbacks ofbreast screening include unnecessary
intervention in patients withbenign breast disease and the lack of
accurate preoperativediagnosis inpatients with screen detected
malignancy. We are prospectively assessing the impact ofthe ABBI
system (Auto Suture, USA) which allows stereotaic biopsy and
excision ofscreen detected lesions.
METHOD: Nonpalpable occultmammographic abnormalities were
evaluated onthe Advanced Breast Biopsy Instrumentation (ABBI)
System. Allprocedures were carried out under local anaesthetic. All data
was collected prospectively.
RESULTS: To date 100 patients have undergone 30 ABBI excisions and
70 core biopsies.1 1 excisions were malignant, 7 DCIS and 12 benign
(including 2 radial scars). Only 4 ofthe 7 patient with DCIS had residual
in-situ disease on furth2r open procedure. Ofthe 6 fibroadenomata 3
were suspicious mass lesions not seen on ultrasound, the rest were
microcalcifications. Median duration ofthe procedure was 70 minutes
(range 35-110). Histology ofthe core biopsies revealed malignancy in 9.
DCIS in 17 (ofwhich 4 were invasive ductal on further open biopsy) and
benign in 44 (2 had invasive disease on wire mark-up biopsy. The
procedure was well tolerated in all patients with no complications.
CONCLUSION: the ABBI systemprovides awell tolerated accurate
diagnostic intervention forpatients with screen detected breast lesions. It
facilitates accurate pre-operative diagnosis and may have apotential for
therapeutic applications inpatients with very small screen detected
cancers.
CLASSWICATION OF BREAST DISEASE
041 WITH MM USING NEURAL NETWORKS
AJ. Knowles, B. Issa, S. Burton, P. Gibbs, G-P. Liney, and L.W.
Turnbull, MRI Centre, Hull Royal Infirmary, Hull, HU3 2JZ
Introduction Due to overlap in the morphological appearance of
benign and malignant lesions on post-conta scamning, dynamic
contrast ha MR imaging (DCE-MRI) has been used to aid
diff iation. This study investigates the acacracy ofneural
networks to analyseDCE-MR compared to an experienced
radiologist.
Methods DCE-MRI was performed on 103 patients (69 malignant, 34
benign). Twenty-five images were acquired with atemporal resolution
of 11.6 sec. Regions ofinterest were drawn around the entire
abnormality and time-course data for each pixel presented to avariety
ofneural network architectures. The radiologist then examined both
thetime course data and the post-contrast images separately and then
in combination-
Results The probabilistic neural network achieved the best
classification with an accuracy of900/o, compared with 76% for the
radiologist utilising the time course graphs alone. With the addition of
morphological information, the accuracy ofthe radiologist increased
to 89% forthe post-contast images and 970/o forthe post-contrast
images and time course data combined
Condhsions Neural networks offer areliable, fast and operator
independent method for analysing DCE-MRI data. They appear to
provide a comparable accuracy to a radiologist utilising post contrast
images alone.
043 ACOMPARISON OF THE CARE RECEIVED BY
WOMEN WITH BREAST CANCER LIVING IN
AFFLUENT AND DEPRIVED AREAS, U Macleod', CJ Twelves2, S
Ross3, C Gils, GCM Watt', 'Dept ofGeneral Practice, University of
Glasgow, Woodside Health Centre, Barr Stret, Glasgow, G20 7LR,
2CRC Dept of Medical Oncoy, 3Heakth Saec Resech Unit,
University ofAbrdeen,4West ofScodand Cancer Survilla Unit.
Ai: To describe and compare the presentatio and pattern of care
received by women with breast cancer fiving in affluent and deprived
areas.
Methods: Case note review of the hospital and general practice case
records ofwomen who were di d with breast cancer in Greater
Glasgow Health Board in 1992 and 1993, and who lived in Deprivation
categone (Css' Indsk) 1,2 (kast deprived, n = 157)and 6,7 (most
deprivd, n = 264)at time ofdiagnss.
Resdt: Deprivaion did not affect the patholgical prognostic factors
at time of presentatio with primary breast cancer. However, more
women frm deprived areas pesented with locally advanced or
metastatic disease(15.4% v 6.4%/, X2= 7.42, p = 0.006). The time
fiom GP's ltter to clnic visit was shorter in women from affluent areas
(afflunt: nmfian 6 days, IQR I to 14; deprived.: menn 7 days, IQR 4
to 20, Z = -2.89, p = 0.004), and the time to surgey firo clinic visit
was also shorter ( affluent: median 15 days, IQR 9 to 24, deprived
median 17 days, IQR 11 to 28, Z = -2.10, p=0.036). Comsulation
paters in geal pracic by the second year after di s showed
women in deprived ares c ing more fre n than women in
affen areas (c ing >12 times per year: 27.0%/6 v 15.9/. X2=
12.67, p = 0.027).
C.idusioms In this study, women living in deprived areas were more
likely to present with large, advanced cancers than women living in
affluent areas, to wait loger to be seen at the clinic and longer for
argey. By 2 years after diagnis, more women in deprived areas
c d to consul in excess ofonce a month innrimarv care.16 Oral Presentations: BIOLOGY & RADIATION
Biodistibution and pharmncokinetics of llln-
044 DTPA4abelled stelth liposomes (IDLSL) in a
human tumour xenograft model. K Harringtona, G
Rowlinson-Buszaa, P Uster', R Abrat, S Stewarta. ICRF Oncology Unit,
Hammersmith Hospital, UKa. SEOUUS Pharmaceuticals Inc., USAb.
Purpose: To study the biodistribution and pharmacokinetics of
IDLSL in female nude mice bearing the human KB head and neck
squamous cell cancer tumour xenograft (HNSCCXT) in order to
examine possible applications of Stealthliposome-targeted anti-cancer
therapies.
Materials and Methods: KB tumour cells were grown in RPM1-
1640 medium containing 100 U/ml penicillin and 100 gg/ml
streptomycin, supplemented with 10% foetal calf serum at 37°C in a
humidified atmosphere of 5% CO2 in air. HNSCCXT were
established by injecting 5 x 106 cells subcutaneously in the flank of
nude mice. Tumour-bearing mice received an intravenous injection of
either 100 pi IDLSL or 100 gl ttIn-DTPA, each containing 0.37
MBq ofradioactivity. Mice were dissected at specifictime-points and a
wide range of tissues were taken and weighed and their content of
radioactivity was determined by counting them in a gamma counter.
Standards of the injectate were counted to correct for physical decay of
the radioisotope.
Results: The t1/2a and t1/25 of IDLSL were 1.1 and 10.3 h,
respectively. Tumour uptake was maximal at 24 h at 5.5 ±3.0 %ID/g.
Significant reticulo-endothelial system uptake was demonstrated with
19.3 ±2.8 and 18.8 ±4.2 % ID/g at 24 h in the liver and spleen,
respectively. Other sites of appreciable deposition were the kidney,
skin, female reproductivetract and to alesser extent the gastrointestinal tract. There was no indication of cumulative deposition ofIDLSLin
the lung, central nervous system, musculoskeletal system, heart or
adrenal glands. The t1/2a and tli, of unencapsulated iiiIn-DTPA
were 5 minutes and 1.1 h, respectively, with no evidence of
accumulationin tumour or any normal tissue. Conclusions: (1). Stealth liposomes target HNSCCXT effectively
with high levels of deposition. (2). Encapsulation of iiiIn-DTPA
within a Stealthliposomal matrix dramatically alters its biodistribution
and pharmacokinetics. (3). Stealth liposome entrapment of cytotoxic
drugs and radiosensitisers offers the possibility of developing novel
targeted anti-cancer therapies.
IN VITRO ULTRAFRACrIONATION 046 OVERCOMES RADIORESISTANCE IN
GLIOMA CELLS. S.C.Short and M.C.Joiner, Gray
Laboratory Cancer Research Trust, Mount Vernon Hospital.
Northwood, Middx HA6 2JR.
Low-dose hypersensitivity has beendemonstratedin a series of 14
different radioresistant human tumourcell lines. It produces
increasedcell kill per gray at very low doses. We have used one of
these, T98G, a human glioblastoma cell line to explore whether this
can be exploited in afractionated regime. Single dose data using
T98G suggest that a dose of0.4 Gy produces marked
hypersensitivity. The effect of consecutive 0.4 Gy doses at varying time intervals in vitro, suggests that a second hypersensitive
response can be obtained if the second dose is given after a four
hour interval. We have extended this to look at the effect of three
consecutive 0.4 Gy doses at four hour intervals and have shown
that cell killing is significantly greater than after a single dose of 1.2
Gy (p<0.01). Further, over a period of 5 days we have compared
0.4 Gy 3times a day at four hour intervals to 1.2 Gy once each
day. Theultrafractionated regime produced significantly increased
cell kill as measured by clonogenic survival (p<0.01). This is
contrary to the LQ prediction and supports the idea that low-dose
hypersensitivity can be exploited in a fractionated regime and may
prove useful in thetreamnt of radioresistanttumours.
045 l;MODIFICATION OF HUMAN TMOURBLOOD 045 FLOW USN-G PENTOXIFYLLINE AND CARBOGEN.
K A Goodchild1. SA Hill2. DJ Chaplin2. PJ HoskJinI and
Ml Saunders IMount Veanon HospitaL Northwood. HA6 2RN. 2Gra) Laboratory
Cancer Research Trust PO Box 100. Northwsood. HA6 2JR
Introduction Anticancer treatments require well oxygenated tumour
cells for maximum effect. Methods to improve human tumour blood
flow- thereby increasing oxygenation may be an important means of
enhancing therapy. In animal tumours pentoxifylline has been reported
to increase oxygenation, blood flow and radiosensitivity. Improvement
in oxygenation in human tumours has also been shown after
administration ofpentoxif 1line and carbogen (950/%02.50/%C02).
Aim To study the effect of pentoxifylline and carbogen on human
tumour perfusion.
Methods Microregional tumour perfusion was measured in superficial
tumours using laser Doppler microprobes in 15 patients with
histologically proven malignancy. Patients received a single oral dose
of either 1200mg or 1600mg of pentoxifylline. Two hours later, at the
time ofpeak drug levels, carbogen was administered and blood flow was
recorded using up to 6 microprobes for 30 minutes in total: 10 minutes
pre-carbogen. 10 minutes during carbogen and 10 minutes post-
carbogen.
Results Although there was marked heterogeneity in response, both
between tumours and between different microregions within a single
tumour, there was an overall increase in relative laser Doppler flow
during carbogen breathing in patients pre-treated with pentoxifylline at
both dose levels. No patient showed a decrease in tumour perfusion.
Previous studies hase shown that carbogen alone may cause either
increases or decreases in laser Doppler flux, such that no overall change
is apparent.
Conclusions Pentoxifylline in combinationwith carbogen can increase
blood flow in human tumours. This may provide a potential therapeutic
gainwhen used in combinationw-ith radiation or chemotherapy.
047 FERTILITY AFTER IODINE-131 THERAPY
FOR THYROID CANCER, L Vini, B. Pratt,
A. Al-Saadi, V.R. McCready, C. Harmer. Thyroid Unit, Royal Marsden
NHS Trust, Downs Road, Suton, SM2 5PT, UK.
A m: This is a retrospective review to assess
fertility following treatment with radioiodine in
patients with differentiated thyroid cancer. Material:
391 patients (297 women and 94 men) under the age
of 40 at the time of treatment were identified. All
had well differentiated thyroid carcinoma (298
papillary and 93 follicular) initially treated with
total thyroidectomy. Only one dose of 1311 (3GBq) was
given to ablate thyroid remnants in 261 patients; the
remainder received more than one dose (cumulative
activity 8.5-47 GBq) for residual, recurrent or
metastatic disease. Information is available for 252
female and 81 male patients. Results: Menstrual
changes lasting 2-8 months were reported by 29
women. 198 children were born from 161 female
patients and 68 children were fathered by 48 male
patients. Four premature births and 3 spontaneous
abortions were registered. Only one female has
failed to conceive. Malformations have not been
reported. The remaining patients had no wish to have
children. Conclusions: The risk of damage to the
gonads of patients treated with 1311 appears to be
low and lacks clinical impact. Radioiodine therapy is
a safe procedure in this aspect.Oral Presentations: BIOLOGY & RADIATION 17
048 DNA DAMAGE AS A PREDICTOR OF
NORMAL TISSUE RESPONSE TO
RADIATION. AE Kiltie, AJ Ryan, R Swindell, JBP Barber, B
Magee, CML West, JH Hendry. Section of Genome Damage and
Repair, Paterson Instie for Cancer Research, Chistie Hospital NHS
Trust, Manchester M20 4BX
Fibroblast clonogenic assays ofitrnc cell radiosensibvity have been
developed which are predictive for normal tissue late responses, but
which are too time consuming to be of routine clinical use prior to
radiotherapy. As a relationship between fibroblast clonogenic
radiosensitivity and residual radiation-induced DNA double strand
breaks (dsb) as studied by PFGE has been shown by a number of
groups, a study was performed to establish whether this measure of
DNA damage was predictive for normal tissue responses to radiation
Patients treated for breast cancer nine to 15 years previously, with
radiotherapy following wide local excision, were studied using a
modification of the LENT SOMA score for breast cancer A 5 mm
punch biopsy was taken from the buttock Fibroblasts from the lower
dermis were grown in tissue culture and assayed using PFGE. The
nonnalised values for the fraction ofDNA released following 150 Gy
were from 4.1% to 12.4%, representing a 3.0-fold range of values
There were weak but significant correlations between the assay result
and the fibrosis score (r=0 46, p=0.003), the combined fibrosis and
retraction score (r=0 45; p=0.004), and the overall LENT score
(r=0.43, p=0.006). Measurement ofresidual DNA dsb may be of use
in the fiiture, probably in combination with other assays, to predict
normal tissue reactions after radiotherapy.
This work was fiuded by the Christie Hospital Endowment Fund and
the Cancer Research Campaign
050 TUMOURRADIOSENSITIVITY IS AN INDEPENDENT
PROGNOSTIC FACTOR N CERVIX CANCER
SE Davidson'.CML West2,SARoberts',RD Hunter',
Christie CRC Research Centre, Manchester M20 4BX.
The prognostic value of pre-treatment measurements of tumour
radiosensitivity (surviving fraction at 2 Gy, SF2) in 128 patients with
stage I - Ill cervical carcinomas undergoing radiotherapy was studied.
The median follow-up time was 47 months. In a univariate analysis
stratfying patents according to the median value, radioseniivity was a
significant prognostic factor for overall survival, local control and
metastasis-free survival. The 5-year survival rate for patients whose
tumours had SF2 below the median was 81% and was significantry
greater than the rate of 51% for those with SF2 values above the
median. In bivariate analyses, SF2 was shown to be independent of
disease stage, tumour grade, patient age, colony-forming efficiency and
tumour diameter. In a multivariate analysis, radiosensiivity was the
most important variable and, after allowing for this, only stage was a
significant independent predictor of treatment outcome. These data
indicate that for patients treated with radiotherapy for cervical
carcinoma, pre-treatment Ltumour radiosensituvity is an important
prognostic factor and contnrbutes to prognosis independently of other
establshed and putative parameters.
049 HIGHTUMOUR ANGIOGENESISCORRELATES
WITH POOR SURVIVAL IN CERVIX TUMOURS
R Cooper, J Logue, S DavMism RHunter, D Wilks, C West
Chnstie CRC Researdi Cantre. Mandhester, UK
gpse: To determine the relationship between tumour angiogenesis
and outcome in Ill patients with stage Ib-HlIb carcinoma ofthe cer ix
treated by radiotherapy
Methods: Formalin fixed paraffin embedded random tumour biopsies
were stained using immunohistochemistry for anti-Factor VHIl-related
antigen Vascularity was measured by scoring the disance from a
random point to the nearest microvessel within the tumour (DTCMV)
and by counting the number ofmicrovessels in areas of
neovascularisation (IMD).
Results: The level oftumour angiogenesis was a significant prognostic
factor for outcome. Patients with IMD counts below the median had a
5-year survival level of65% compared 50°/o for those with counts
above the median (p=0.038). High vascularity as measured by both
IMD and DTCMV was also associated with increased local relapse
(p=0.028 and p=0.060, respectively). There was a trend towards
improved metastases-free survival for patients with less well
vascularised tumours but this was not significant for either method.
There was no significant correlation between either DTCMV or IMD
and tumour stage, grade or volume.
Conclusion This large study on a homogeneously treated group of
patients indicates that a high degree oftumour angiogenesis is
associated with poor prognosis in carcinoma ofthe cervix treated by
radiotherapy
Supporedby the Cancer Research Campaign
051 CELLULAR RESPCNSE TO IONISING RADIATION IN PATIENTS WrTH MUTATIONS IN THE BRC41 GENE.
TJ McMillan, J Peacock, R Eeles, HD Platte, A. Pearson, J Tawn, P Danie, R
Berry, Department of Biolgical Sciences, Lancaster University, Lancaster
Radiation Research Department, Irsbtute of Cancer Research, Cotswold
Road, Sutton, Surrey, Radtherapy Department, Royal Marsden Hospital,
Downs Road, Sutton, Surrey, Westlakes Research Insttute, Moor Row,
Whitehaven, Cumbna
The aim of this study is to establish whether individuals carrying mutatons
in thPe BRCA1 gene have an increased susceptibility to the mutagenic and
cytotoxic effects of ionising radiation. This is a possible concern due to the
influence of other breast-cancer predisposing genetc changes (e.g. TP53
and ATM mutations) being associated with abnormal responses to DNA
damage, the reported radiation sensibivity of brcal knock-out mice and the
known association ofthe BRCA1 protein with proteins involved in DNA
damage processing.
We have exarrined the sen§sitvity to the killing effects of high- and low-
dose rate irradiation in cells from 19 individuals who are members of 5
families with BRC41 mutabtions. From the initial phase ofthe study we have
seen that cells wih mutant BRC41 do not have an extrene sensitvity to
the kiling effect of radiation, though their sensitvity parameters do fall at
the sensibtve end ofthe normal range. In additon we are exanining other
responses to radiation induding cell cycle perturbations and p53 inducton
in these cells as potential indicators of sub-lethal damage. The progress on
these responses will be reported.
This work was supported by the Cancer Research Campaign, UK.18 Oral Presentabons: BIOLOGY & NOVEL THERAPIES
052 ANTI-ANGIOGENIC GENE THERAPY
K. Fifel. L. Buluwelal. A. Miller". R.C. Coombesl.
M. Bowerl. Charing Cross and Westminster Medical Schooll and
Department ofChemistrv. Imperial College. London. UK.
Angiogenesis is recognised as an important target for anti-cancer
therapy, as neoangiogenesis is sital forthe initiation and growth of solid
tumours. A novel gene therapy approach to antiangiogenesis is
described. Briefly. human endothelial cell lines were transfected with
the Herpes simplex virus thymidine kinase (HSV-tk) gene using a
liposome vector. Exposure of transfected cells to ganciclovir (GCV)
resulted in greatly preferential cytotoxicity to the HSV-tk transfected
cells as compared with controls.
Human endothelial cell transfection is known to be inefficient.
Liposomes were chosen as the vector for transfection as thev hase a
better safety profile than viruses. Optimisation of transfection was
performed. usino the SV40,Bgal reporter plasmid, with three
commercially available liposomes (Transfectam. Tfx-50 and DOTAP)
and three supplied by the Department of Chemistry. Imperial Colleoe.
London (DC-Chol/DOPE. ACHx/DC-Chol/DOPE and ACO/DC-
Chol/DOPE). The greatest transfection efficiencies were obtained using
the cationic liposome DC-Chol/DOPE with values of 5.8% for HUV-
EC-C and 9.5% for ECV304 human endothelial cell lines. These are
amongst the best reported figures for non-viral endothelial transfection.
and DC-Chol/DOPE has the advantage of hasing been used in human
gene therapy trials (Caplen et al.. 1995).
DC-ChoL/DOPE was therefore used to transfect cells with HSV-tk. Co-
transfection with a puromycin resistance plasmid was performed to
allow antibiotic selection oftransfected cells. When exposed toGCV for
six days. HSV-tk transfected HUV-EC-C cells demonstrated
cytotoxicity 3logIo greater than controls. and ECV304 cells 2-31oo
greater. The bystander effect was also demonstrated with HUV-EC-C
cells. These results show that non-viral transfection of human
endothelial cells with a 'suicide gene' is a feasible and potentialls
valuable approach to anti-angiooenesis.
Caplen. N. etal. 1995. NanireMed. 1. 39-46.
054 BAX E AND ); NOVEL mRNA SPLICE
VARIANTS OF THE PRO-APOPTOTIC
GENE
A.L. Thomas, C.G. Pnrce, S. Martin, J. Carmichael, J.C.
Murray. CRC Dept. of Clinical Oncology, City Hospital.
Hucknall Road, Nottingham NG5 1 PB.
The ability of a tumour cell to withstand apoptosis is emerging
as an important factor in the development of drug resistance in
tumour cells. Apoptosis in response to genotoxic stress is
mediated by the Bcl-2 family of proteins, which indudes Bax.
The bax gene comprises 6 exons and demonstrates a
complex pattem of altemative mRNA splicing. By RT-PCR,
we detected the presence of two new varants, bax E and bax
4, in peripheral blood leucocytes, and a variety of normal and
tumour cell lines. Sequencing of the PCR products indicates
that bax E lacks exons 2 and 3, while bax4 contains an extra
49 bp between exons 5 and 6, arising from a partial deletion of
intron 5. Bax E has a predicted protein of only 1kDa and does
not contain any known functional domains, whereas bax4 has
a predicted weight of 24kDa and contains all domains except
the transmembrane domain. Westem blotting and in vitro
transcription-translation have been used to characterise the
protein products. Currently we are using a transient
expression system to ascertain the functional significance of
these novel genes.
0S3 RADIOIMMUNOTHERAPY OF B-CELL
0 LYMPHOMAS 1WTH IODINE-131 LABELLED
ANTIBODIES: DETERMINANTS OF SUTCCESSFUL THERAPY.
T. M. ilidge; R.French; R.Reid; and M. J. Glennie Lympboma
Research Laboratory, Southampton General HospitaL
Southampton S0166YD.
In this study report we report for the first time the in siso modulation,
biodistribution, and radioimmunotherapy (RIT) of a range of B-cell
specific antibodies in syngeneic B-cell lymphoma animal models.
Initial biodistribution studies enabled accurate organ dose predictions
to be made directly comparing two radiolabelled antibodies directed
against B-cell antigen targets that intemalise to a greater and lesser
degree. The important determinants of effective radioimmunotherapy
in the mouse B cell lymphocvtic lymphoma BCL, and the B cell
tumour A31, were evaluated by comparing the effects of antibodies
against CDI9, CD22, CD40, the invariant chain Ii (CD74), MHC
Class II, versus tumour specific anti-idiotype and isotype matched
control antibodies with and without conjugated Iodine-131. When
treated early in the disease a very high therapeutic efficacy has been
demonstrated (>90% cure), targeting highly expressed antigens that
internalise poorly using low doses (2 MBq) of '3l anti-CD74 and ""I
anti-Class II antibodies. With larger tumour burdens, delivering an
increased dose of radioactivity to the tumour bearing organs by the
selection of a highly expressed poorly modulating B cell antigen target
(MHC Class II, CD74), has been shown to be of lesser importance
than the selection of an antibody against a B cell antigen where
irradiation and antibody response appear to be synergistic
(Immunoglobulin idiotype and anti-CD40). These results using low
dose RIT hase important implications for clinical RIT strategies in
NHL; strongly suggesting the success of this approach is much more
than targeted irradiation and that antibody and irradiation can be
synergistic in the induction ofapoptosis.
(This work was supported by the Cancer Research Campaign, UK.)
055 DNA VACCINATION WITH A scFs OF THE
ANTI-IDIOTYPE ANTIBODY 105AD7
INDUCES A TH, IMMUNE RESPONSE.
V. Potter. I. Spendlove. and LG Durrant. CRC Department of Clinical
Oncologs. City Hospital. Hucknall Road. Nottingham. NG5 1PB. UK.
105AD7 is a human monoclonal anti-idiotvpe antibody vaccine which
mimics T cell epitopes on the tumour antigen 791Tgp72 and has been
shown to elicit specific anti-tumour T cell immune responses in
animal models and clinical studies. We are investigating w-hether a
scFv DNA construct could mimic the activith ofthe 105AD7 antibodv
vaccine and enhance cytotoxic T cell responses. The cDNA encoding
the heavy and light chains of 105AD7 has been sequenced and wse
have produced a scFv of the V regions joined by a 15mer linker.
Protein of the correct molecular sweight has been detected in the cell
lvsate of E.coli transfected with the scFv and in a eukarvotic in vitro
expression system. Mice were vaccinated sith 100Qig of the scFv
DNA via the IM and ID rouites. As a control the wsell characterised
pCMV-S plasmid which encodes for the HBsAg was used. Both
plasmids. irrespective of route of vaccination have produced specific
antibody responses. to their respective antigen. which are
predominantlS of the IgG2a subtype. In contrast vaccination with the
105AD7 antibodv and HBsAg recombinant protein produced an IgGi
response. The predominant IgG2a antibody response produced by
DNA vaccination is a feature of TH, immune responses. associated
with cell mediated cytotoxicity. Protein v accines. howsever.
characteristically produce strong antibody (TH ) responses. The
antibod%- titres produced by the 10O5AD7 scFs are consistently lover
than those against HBsAg. this may be explained by the variable and
often poor secretion. as seen in the prokaryotic system. In order to
overcome this problem DNA constructs that produce a scFs dimer and
trimer are being evaluated as these have been shown to be more easily
secreted in many systems.Oral Presentations: BIOLOGY & NOVELTHERAPIES 19
PHASE II TRIAL OF THE BISPECFIC
056 ANTIBODY MDX-H210 (ANTI-HER2INEU X
ANTI-CD64) COMBINED WITH GM-CSF IN
PATIENTS WITH ADVANCED PROSTATE
AND RENAL CELL CARCINOMAS THAT EXPRESS HER2/NEU.
N. J P. Atherton', A. Koletsky2, N. Tchekmedyian3 and R.
CuMow4. 'CRC Institute for Cancer Studies, Birmingham B15 2TH
UK. 2Intercenter Cancer Research Group, Florida, 3Pacific Shores
Medical Group, California. 4Medarex, Inc., New Jersey, USA.
Aim: To evaluate the bispecific antibody MDX-H210 (which combines
a recognition site for HER-2/neu with a triggering sequence for the
high affinity IgG Fc receptor CD64) combined with GM-CSF in
patients with hormone refractory metastatic prostate or locally
advanced or metastatic renal cell cancers that express HER2/neu.
Methods: 23 patients (5 renal, 18 prostate cancer) were trated with
GM-CSF (5 ±g/kg/day by subcutaneous injection for 4 days), followed
by MDX-H210 (15 mg/M2 by intravenous infusion), repeated weekly
for 3 weeks. Patients with stable disease or better with no dose limiting
toxicity were eligible for a second cycle of treatment.
Results: We have seen 2 objective responses in patients with renal
cancer a 52% reduction in the tumour (liver metastases as large as 10 x
12 cm) in one patient and a 49% reduction in the size of a pulmonary
metastasis with clearing of non-measurable lesions in another patient.
We have seen 5 objective responses (>50% decline in PSA) in patients
with prostate cancer 104 to <O.1, 20 to < 0.1, 1 8 to I 1, 872 to 207 and
126 to 58 ng/ml. Quality of life improvements have been noted.
Toxicity with GM-CSF was mild (worst NCI-CTC grade 2). Little or
no additional toxicity was seen in the majority ofpatients after infusion
of MDX-H210; however, in responders, grade 3 toxicity was seen in
both renal cancer patients and 1 prostate cancer patient.
Conclusions: We believe this is the first evidence of clinical response
to immunotherapy in patients with hormone refractory prostate cancer,
and indicates promising potential for MDX-H210 plus GM-CSF in the
treatment ofpatients with renal and prostate cancer.
~ PROMOTER CONSTRUCTS FOR PROSTATE
058 CANCER GENE THERAPY
J Latham, PF Searle, V Mautner, ND James
CRC Institute for Cancer Studies, University of Binmingham,
Edgbaston, Birmingham B15 2TA
Aim: To construct tissue specific promoters based on prostate specific
antigen for use in human gene therapy.
Method: A range of luciferase reporter vectors, using sequences from
the proximal 5' PSA and cytomegalovirus (CMV) promoters for
expression control, were constructed and their tissue specific nature
was explored in a variety of cell types. Assays were standardised using
a CMVIE promoter driven P-Galactosidase reporter vector.
Results: The minimal 5' 650bp PSA promoter showed only low level
non-specific expression. Placing two PSA promoters in tandem also
gave low levels of expression. The addition of the CMVIE enhancer
upstream of the PSA promoter increased luciferase expression
substantially but overrode any tissue specific control the PSA promoter
may have possessed. However, placing a 1400bp PSA enhancer
sequence upstream of the minimal PSA promoter increased expression
in a tissue-dependent manner. A further enhancer placed in tandem
upstream greatly increased expression while retaining tissue-specific
control. Furthermore the level of expression from both the single and
tandem enhancer constructs can be increased 100- fold above their
basal levels when induced with the androgen, dihydrotestosterone.
PSA enhancer tandem PSA-promoter driven ntr, B7-1 and GFP
adenoviruses have been made, and investigations into the tissue
specific nature of these viral vectors in a range of tissue types including
primary prostate tissue is underway.
Conclusions: Prostate tissue specific constructs can be made in vitro
and further evaluation using viral vectors is now underway as a prelude
to clinical studies.
O=57 CD40 EXPRESSION IN BLADDER CANCER
0 7 I PWCooke', NDJames', R Ganesan2, DMA
2 Wallace , A Burton' and LSYoung'. 'CRC Institute for Cancer Studies
& 2Queen Elizabeth Hospital,Birmingham.
Introduction: The CD40 receptor is expressed in many immune cell
types and is known to play a central role in both humoral and T-cell
mediated immunity, being a subject of intense research interest in
recent years. It is also expressed on a variety of carcinomas and may
therefore be of biological significance in the development and
treatment of cancer.
Methods: The expression of CD40 was examined
immunohistochemically in a series of 131 bladder tumours, and the
correlation with known prognostic markers and clinical outcome
assessed.
Results: 79% of the tumours were CD40-positive, with a highly
significant association with both lower stage and lower grade
(p<O.OOl). Superficial tumours expressed CD40 in 89% of specimens
compared to 61% seen in invasive tumours, and in contrast to normal
urothelium, which was mainly CD40-negative. CD40 expression was
not related to any other clinico-pathological variable including
lymphocyte infiltration, Bcl-2, or p53 expression, nor was it an
independentprognostic marker.
Conclusions: The lack of relationship with Bcl-2 staining, which is
normally seen in basal epidenmal cells, may indicate altemative or
abnormal CD40-mediated cell differentiation mechanisms. The diffuse
expression seen in superficial bladder cancer may account for it's
clinically less aggressive behaviour and is likely to be an important
factor in the excellent clinical response seen to BCG immunotherapy. It
also raises the possibility of the future development of CD40/CD40
ligand-based immunotherapy for bladder cancer.
INFILTRATION OF CERVICALCANCER
059 TISSUE WITH HUMAN PAPILLOMAVIRUS-
SPECIFIC CYTOTOXICT-LYMPIiOCYTES
EML Eva' S Man, AS Evans*, LK Borysiewicz; Depts. of Medicine
& Gynaecology*, University ofWalesCollege ofMedicine, Cardiff.
Introduction CytotoxicT-lymphocytes (CTL) specific for high-risk
HPVs(16and 18) haverecently been found in theperipheral blood of
cenrical cancer(CC)patients(Borysiewicz et al, 1996; Ressing et al,
1996) but theirrelevance at sites ofdisease is unclcar. Two HPV-16
E7peptides were used to map the distrbution ofHPV-specifc CTL in
peripheral blood (PBL), draining lymph nodes (LNL) and tumours
(TIL) ofCCpatients.
Methods HPV and control peptides were used to restimulate PBL,
LNL and TIL in vitro. Peptide-pulsed dendritic cells were used to
induce primary responses in control subjects. Limiting dilution
analysis in the absence ofspecific antigen stimulation identifiedCT1
lysing target cells infected with a recombinant vaccinia virusencoding
modified forms of HPV-16 and -18 E61E7 protein sequences (TA-
HPV)(Borysiewicz et al, 1996).
Results We identified HLA-A*0201-restricted HPV-16 E7 peptide-
specific CRI, in peripheral blood (4/5), draining lymph nodes (3/4)
and tumours (1/3) of CC patients. All peptide-specific lines also
recognised target cells infected with the recombinant vaccinia virus,
TA-HPV. In 4/4CC patients, thefrequency ofCiT specific for TA-
HPV was found to be higher in tumours and lymph nodes compared
with peripheral blood. HPV-specific CRL were not identified in any of
7 healthy controls, but primary responses could be generated by
peptide-pulsed dendritic cells (414). HPV 16 E7 peptide-specific
clones were expanded in vitro, and analysis showed restricted TCRBV
segment usage, although CDR3 regions were not oligoclonal.
Conclusion Although the role of virus-specific TIL in vivo has not
been determined, thisstudy raises the possibility that CRL induced by
vaccination oradoptively transferred can infiltrate sites of disease.
References Borysiewicz LK et al (1996) Lancet. 347, ppl523-1527;
Ressing MEet al (1996) Cancer Res. 56, pp582-588.20 Oral Presentatons: BIOLOGY & NOVEL THERAPIES
PHASE I STUDY OFASCENDING DOSES OF
060 THE CYTOTOXIC IMMUNOCONJUGATE CMB-
401 (hCTMO1 - CALICHEAMICIN) IN PATIENTS
WITH EPITHELIAL OVARIAN CANCER. A M Gillespiel, T J
Brrndhen12, S Y Chan2, J Owen1, A P Farnsworth3, M Sopwith3 and
R E Coleman'. 1. Yorkshire Cancer Research Dept of Clinical
Oncology, Weston Park Hospital, Sheffield, UKI 2. Dept Clinical
Oncology, City Hospital, Nottingham, UKI 3. Celltech Therapeutics
Ltd. Slough, UK.
We have performed a Phase I study of the cytotoxic immunoconjugate
CMB401 (hCTMOl - calicheamicin) in women with epithelial
ovarian cancer (EOC). hCTMO1 is a genetically engineered human
antibody directed against polymorphic epithelial mucin which binds
preferentially to EOC (tumour blood ratio 8:1 - Cancer Res
1996;56:5179-5185). The objectives of this two centre study were to
identify end-organ toxicities and to establish maximum tolerated dose
(MTrD). Tumour response was also monitored.
Methods: 34 patients were recruited with satisfactory WHO
performance status, aged 20-75 and with progressive EOC not
amenable to platinum/standard therapy. Patients received up to four
cycles of a dual infusion of35mg/m2 hCTMO1 pre-dose' followed by
ascending doses of CMB401 - a regimen which miimises drug
uptake in normal tissues whilst enhancing delivery to the EOC.
Results: CMB-401 dosing commenced at 2mg/i2 and p ed via
seven cohorts to 16mg/m2. CMB401 was generally well tolerated.
Transient malaise and emesis occurred, necessitating routine
prophylaxis. WHO grade 3/4 toxicities, irrespective of causality,
included: haematological (anaemia 21%, granulocytopenia 9%,
thrombocytopenia 9%); liver and renal (transaminases 3%, alkaline
phosphatase 6%, urea 3%); sepsis 3%; haemorrhage 6%,
nausea/vomiting 76%; pulmonary 6%, conscious stage 6%. MTD was
defined at 16mg/in2 by malaise, haematological toxicities and the
expenence of gastro-intestinal haemorrhage. Dunrng the study four
patients had a greater than 50% reduction in CA125, and four patients
had imaging evidence ofreduction in tumour bulk
Conclusion: CMB401 appears to have an acceptable toxicity profile
with initial evidence of activity against EOC. Development will
continue in a Phase II studv.Oral Presentations: GASTRO INTESTINAL TUMOURS 21
061 EPIRUBICIN (E), CISPLATIN (C), UFT (U) - "ECU"
IN UPPER GI CANCER: LOSING THE PUMP, BUT
KEEPING THE EFFICACY.
MT Seymour JT Dent. *D Papamichaee, HE Cresswell & G Uilson.
ICRF Cancer Medicine Research Unit. Cooknidge Hospital. Leeds &
*St Bartholonmew's Hospital, London
Backsround: 'ECF:- 3-weekly E & C plus protracted venous infu-
sion (PVI) fluorouracil (F), is a highly active combination with superior
activity to FAMTX in gastroesophageal cancer (JCO 15:261) and im-
pressive response rates in breast cancer (JCO 12:1259) and other
solid tumours; however, the inclusion of PVI F adds to its morbidity
and cost. Oral UFT generates plasma 5FU levels similar to PVI F
(Proc ASCO 14:1498). We therefore performed a dose-escaltion
pilot study of ECU', in which F is replaced by oral UFT, at escalating
doses, together with weekty folinic acid (FA). Method: 30 previously
untreated patients (pts) with advanced upper GI cancer wera entered
(73% gastroesoph.; 17% biliary.; 10% pancr.). 29/30 had PS 0-1;
median age, 58. All received E, 50 mg/M2 and C, 60 mg/iM2 on day 1,
and FA 45 mg p.o. on dl, 8 & 15 of a 21-day cycle. UFT was taken
12 hourly, dl-21, at escalating doses in cohorts ranging from 150 to
325 mglm2/d. Up to 8 cycles were given. Pts with measurable dis-
ease were assessed by CT or MRI every 12 weeks. Results: Of 12
pts started at, or escalated to, 265 mg/m2/d UFT, 4 required dose re-
duction, making this the MTD. Of 8 pts treated at 325 mg/mr2nd, 4 re-
quired UFT reductions. Most UFT dose reductions were for mild (CTC
grade 2) but persistent fatigue, nausea or diarrhea, rather than se-
vere acute toxicity. However, one pt each at 265 and 325 mg/m2/d
had grade 4 toxicity (ileus/small bowel obstruction) which may be re-
lated to UFT. Only 2 episodes of gr 3 neutropenia were recorded, and
no neutropenic sepsis. 17 of the 30 pts on this pilt study had as-
sessable disease. Of these there were 2 CR and 6 PR (RR = 47%
overall, 57% in gastroesoph. cancer). Conclusion: 'ECU" is gen-
erally well tolerated at the defined MTD, with activity comparable to
ECF in gastroesophageal cancer. It is a promising altemative to ECF
and deserves further, randomised evaluation.
063*2 ARTIFICLALNEURAL NETIWORKS FOR THE
PREDICTION OF OUTCOME FOLLOW'NG SURGERY'
FOR GASTRIC CANCER PJ Drew. L.Bottaci. P.Magee. *I.M.C.MacintTe.
M JKerinn J.R.T Monson. G.S.Duthie The Unisersiti ofHull Academic Surgical
Unit. Castle Hill Hospital & *Western General Infirmar. Edinburgh
An artificial neural netxwork (.ANN) is a form ofcomputer artificial
intelligence that is able to learn non-linear causal relationships
between established data and use this knowledge to ansu-er questions
about data to Ahich it has not been exposed. We compared a neural
netxork analx-sis With the traditional statistical approach for the
prediction ofoutcome following surgery for gastric cancer.
ANN's u-ere designed with 60 input xariables in the first laver.
0.2.3.4.5.6.7.15.20.25 or 30 hidden "neurones" in the second layer and
a simple positive/negative output. Data from 183 patients was
utilised: 133 to train and 50 to validate each ANN for the prediction of
death at 12 months. The neural netu-orks were then compared against
traditional multivariate anal sison 10 randomlv selected validation
data sets.
The AtNN's achieved a mean sensitivitv of0.62. range 0.61-0.65 and a
specificitv of0.77. range 0.73-0.79 with a mean overall accuracv of
0.71 (95%C.I. 0.57-0.83) as opposed to the traditional multivariate
analvsis which achieved a mean sensitivitx of0.56. range 0.43-0.79
and specificity of0.68. range 0.52-0.85 with a mean overall accuracx
of0.62 (95%C.I. 0.49-0.75).
The failure to improve on the accuracy ofthe traditional linear
statistical methods may be due to either too small a learning set. or
mathematically too simple a problem. This accepted. in practical
terms. ANN's provide a more consistent method ofprediction of
outcome gastric following gastric cancer surgen-.
062 OXAUPLATIN,5-FLUOROURACIL (FU) & FOUNIC
ACID (FA) FIRST-UNE COMBINATION THERAPY
IN COLORECTAL CANCER: RESULTS OF A PHASE IN TRIAL.
MT Seymour'. J Cassidy2. C WIlSon3. D Papamichael4. M Homern5. A
Figer5 & A de Gramont7 ' Hp-L : 2Unv Hosp-Aberdeen:
3Addenbrookes Hosp-Cambridge 4St Bartholmws Hosp-London.- 5De-
bioparm-Pans; 6Med. Cen. Petach Tikva-lsrael.- 7H6p St Antoine-Pans
Background: Bolus + infusion FU with FA, given over 48 hrs each
fortnight, is a popular and well-tolerated treatment for advanced colo-
rectal cancer and, in a previous trial, gave superior results to
standard Mayo 5-day bolus FU/FA (JCO 15:808. '97). This study
was designed to evaluate the addition of oxaliplatin to this schedule.
Patients/Methods: From Aug '95 -Jul '97, 420 pts with measurable
colorectal cancer at 37 centres were randomised to receive either [A]
FA 200 mg/M2 over 2 hrs, then FU 400 mg/M2 bolus and 600 mg/M2
over 22 hrs, days 1+2 every 2 weeks; or [BJ the same FU/FA regimen
plus oxalipatin 85 mg/M2 over 2 hrs on day 1. Treatment was contin-
ued until progression or toxicity. Randomisation was well balanced for
primary site (colon in 72%[A] vs 70%[B]), performance status (= 0 in
48%[A] vs 43%(BJ), number of metastatic sites (>1 in 60%fA] vs
570A[B]) and prior adjuvant chemo (20% in both arms). Tumour
measurements were made every 8 weeks and all responses sub-
jected to independent radiological review. Results: Median PFS (all
pts) is currently 27.8 wic [A] vs 39.6 vwk [BJ. A protocol-planned in-
terim analysis on the first 200 pts shows response rates (RR) of 26%
[A] vs 57% [BJ (p<0.05). Both regimens were well tolerated. Toxicity
analysis in the first 200 pts shows slightly higher rates in [B] of CTC
grade (gr) 3-4 diarrhoea (12% vs 2%), vomiting (7% vs 1%) or sto-
matitis (6% vs 0%). Asymptomatic neutropenia was commoner in [B]:
gr 3 in 41% (vs 6%) pts, and gr 4 in 13% (vs 0%), but severe infec-
tion occurred only 1% in both groups. 15% of pts in [B] experienced
gr 3 neurosensory symptoms. Conclusion: The good activity and the
excellent tolerability of the control schedule is confirmned. The addi-
tion of oxaliplatin substantially enhances its activity with a definite but
easily manageable increase in toxicity. Final anatysis of all 420 pts
will be presented at the meeting.
PANCREATIC CANCER DE3ATHS IN SLRGICAL CARE
064 M A Jahan. F Marjoribanks. S J Nixon. A M
Thompson. Department ofSurgery. Ninex-ells
Hospital & Medical School. Dundee. Scotland
Aims andmethods -The Scottish Audit ofSurgical Mortality (SASM)
collects data on the management ofall patients who die in surgical
x ards in Scotland. The aim ofthis studyw-as to identify criteria and
standards for future audit ofdeath from pancreatic cancer. Results-
During the first 3 years ofthe SASM (1994-1996 inclusixe). there u-ere
334 deaths in surgical wards out of 1650 total deaths from pancreatic
cancer in Scotland: ofthose admitted from the community 165 (750 o)
x-ere emergencv admissions. 134 (40'%) had an endoscopic. surgical. or
a radiological procedure. In 147 (44%) patients the treatment u-as
limited and 94 (28%) had terminal care. Seventx (530%) operations u-ere
performed as urgent or emergency. 18 (5.4%) had an open and shut
laparotomy. and 8 (2.4%) deaths follox-ed pancreatic resection. In 21
(21 134) patients there x-ere intraoperative technical problems and 25
(25/134) patients required a second procedure. Adverse factors in
surgical management were identified in 16 (16/134) patients and of
anaesthetic management in 6 (5%) patients. The decision to operate and
the choice ofoperation could haxe been improved in 15 (15 134)
patients. Thirteen (17.50%) patients in x-hom HDUITU was desiarable
were denied access. One in fixve deaths x-ere associated with potentially
axoidable or treatable co-morbiditx. The cause ofdeath in 2500 ofcases
xere potentially avoidable and treatable. Conclusions- Based on the
result ofthis study. patients with pancreatic cancer should be admitted
electively to hospitals with adequate facility for modem staging
techniques. management. and peri-operatixe monitoring facilities to
reduce the unacceptably high premature mortality obserxved in this
studv.22 Orcl Prstatksns GASTRO INTESTINAL TUMOURS
PERCUTANEOUS NEEDLE PHOTODYNAMIC
065 IHERAPY
OF PANCREATIC TUMOURS
W R Lees, A RGillams. D Whitelaw, A Hatfield. S G
Bown. Department of Medical Imaging, The
Middlesex Hospital, Mortimer Street London, UK.
PURPOSE: Simple and effective methods of debulking small
pancreatic tumours do not presently exist PDT offers the potential of
desotuction ofsignificant volumes of tumour tissue within the pancreas
using fine needles to deliver laser fibres.
METHOD: Seven patients were trated over a 16m period using 4-6
19g needles delivered into the head of the pancreas with a 17 mm
spacing 5 days after sensitization with the agent MTHPC. Twenty
joules of energy from a diode laser was delivered at each treatment
staton. 11 seven patients had stents decompressig the previously
obstructed biliary tree. A combination of CT and ultrasound guidance
was used to guide needle delivery. The effectiveness of treatment was
assessed at five days with dynamic contrast enhanced CT where
devascularisation of the pancreas was seen as zero enhancement.
Follow-up scans were performed at lm, 3m, 6m and 12m.
RESULTS: All 7 patients tolerated the procedure well but experienced
some systemic disturbance following the procedure in the first 3 days.
Around each treatment station, the devascularised region was 13-18
mm in diameter and the total volume of necrosis was 12-36 mls. In
three cases, ulceration of the medial wall of the duodenum was noted
on endoscopy at five days. This was not clinically significant in any of
the patients and had healed by three months. All seven patients remain
alive. (Range 2-16m. median of 7m from treatment.)
CONCLUSION: Percutaneous photodynamic therapy appears a safe
and well-tolerated method ofdebulking pancreatic tumours. It's impact
on survival should emerge rapidly from a larger series with longer
follow-up.
C*7 NEOADJUVANT CHEMORADIOTHERAPY
IN CARCINOMA OF THE OESOPHAGUS.
E.W.Toy,T.D.Crosby,D.J.Borey, G.W.Clark,
P.D.Carey,T.S.Maughan, Cardiff, U.K
Long term outcome m carcnoma ofthe oesophagus is poor. Recently Walsh et al
(1996) and Urba et al (1997) have reported improved results following combined
modality neo-adjuvant treatment
17 patients, mean age 61 yrs (46-73)with biopsy proven carcinoma of the
oesophagus(1O adenocarcioma, 7 squamous cell) wee treated with neo-adjuvant
chm lradiodx;apy after stagig with CT and endoloninal uhrasound. It w-as
aimed to give 40 Gy in 15 fiactions via a 2 phase tediqique (30 Gy in first 3
patients) with 2 cycles ofCisplatin 80 mg/m2 day 1 and 5-FU Ig/ m2 days 2-5 q
28 d, the first cycle conunrre with RT. Restging was performed pirior to
sugry.
All received 100.!. of the prescribed radiation dose. 2 patients required a
treannentbreak due to toxicity. 14 patients received 100*/. doses of
cherotherapy.2 had dose reductions.1 declined a second cycle.3 required a delay
prior to cycle 2. 8 (47%) of patients experienced toxicities of grade 3 or
4,(myelosupression 29%, diarrhoea 12Y,dysphagia 6%, vomiting 6/., mucositis
6%) 1 patient died prior to surgery. 15 patients proceeded to surgery at a median
time of41 days post ceotherapy( 5-101). 4 died post-operatvely from serious
repratory comlicaions. Dysphagia scores pre-operatively were improved in
43% and worse in 31%., but this did not crrelate with tumour response. EUS was
repeated in 12 cases pre-operatively suggesting 25% dowustaging. 17%
progresson on TNM criteria. Comparison of initial staging with pathological
staging was possible in 14 patients and revealed: 64% downstaged, 29%
pogression and 7Y% stable dise following cheorxadiation. 4 (29%.) had a
coplete pathological response. Subgro anlysis of reponse shows that
squamous carinomas respond better to this regimen than a p=
0.04 Fishers exact test). A Kaplan-Meier crude survival cuarve shows a 61%
probability ofone year survival (median follow up of suvivors, 61 weeks )
Ceudusios: Use of the dyspbagia score and EUS are poor in determining
tumour stagig post chemoradiation. The response of the squamous cell tumours is
encouraging, whilst that of the adenocarcinomas is partculary disappointing It
suggests that different regimens may be indicated for the tv pathologies. It is too
early for a survival improvement to be confirmed but any benefits were at the cost
of significant toxicity. Whilst neo-adjuvant chemoradiation may improve survi1al
the optimal regime remains to be defined.
066 A PILOT STUDY OF SPHINCTER-
SPARING SURGERY, ENDOLUMINAL &
EXTERNAL BEAM RAD IOERAPY IN RECTAL CANCER
AC McDlnald*1, M Herthsmaim2' C Makin3 and SMyint.
ICLattebridge Centre forOncology, andDeprments ofSurgery,
2RoyalLiverpool and 3Arrowe ParkHospitals, Mrseide UK
Coklomy is an invtable acomaim to aboioprna
resion (APR). Betwen 1991-7, 38 seleted patients with well or
moderately I TI (16pts) or T2 (22pts) cancers of the
distal rectum (36pts < 8cm firm anal margm) were traed racally
Ing anal cr techniques. Most patients were ekdlely
(median age 74, range 42-89 yrs), many (14pts) with n
medical ing APR Twenty-two pts received exteral
beam r apy (EBRT) before (15pts) or after (7pts) tras-anal
tumour rectio (TART, utfiing tras-anal enoscopic micr
in 12pts). Three pts unewen tras-anal umour resecon and
contact radiatio boo using the Papllon technique. Thirteen pts were
trated using only no-sucal t es 7pts receved radical
contact radiothepy and 3 f pts recived initial EBRT and a
local coit boost. Conconitant 5-FU (750mg-lg/m2lday
x 4, weeks 1 & 4) was given with EBRT in selIcte pts of good
-M status (6pts).
Treatment was well toleraed and toxicaes generally mild (< RTOG
gd 2). Three ptsfailed torespond filily to initial non-srgical treatment
and a further 3pts have recurred locall fter 4-9 months. Each has
undergone srgical savage (5=APR; 1=TART). A ftuther patient
developedmetas'a_ic disease after 3 yrs; median follow upperiod is 24
months (range
= 464 months) and shncter preservaton was
achieved in 33pts (87%e). This is a highly selected seres, however
widin this group the teconsesving t is - are well
tolerated and permit good rates oflocal control; this approh merits
evauation infiuther, randonised, suies.
e SOCIOECONOMIC STATUS AND STAGE AT
CW 8 PRESENTATION IN COLORECTALCANCER,
MV Ionescu, IS Tait, RJC Steele, Dept of Surgery,
Ninewells Hospital and Medical School, Dundee DDI 9SY, UK
Introduction: Early diagnosis ofcolorectal cancer (CRC) is
important and several studies have shown wide variation in stage at
presentation by district ofresidence. The reasons for this are not clear
and this study has evaluated Dukes' stage at presentation relative to
scioeconomic status, in a stable population (Tayside, Scotland).
Met.dis: 777 consecutive patients underwent resectional surgery for
CRC from 1991 to 1997. Dukes' stage was documented and
socioeconomic status rated by Carstairs Score (CS), a Deprivation
Index based on Postal Code. Patients were stratified into Groups 1-4
by quartiles, according to CS, with group 4 having the highest score
(i.e. the highest deprivation). Dukes' stage between groups was
analysed by: Xztest. Xfor trend and odds ratio (OR).
Results: The mean age was 69.5 years (median 71 years; range 30-95
years) and the male:female ratio was 1:1.12. The proportion of
patients with Dukes' stage A tumours was lowest in Group 4 (Table)
(p<0.0IX-test; p<0 005 X test for trend). In group 4, OR for Dukes'
A was 0.574 [95% confidence interval (CI) 0.38;0.85], and OR for
Dukes' B or C was 1.74 [95% CI 1.17;2.58].
Groups n Carstairs
Rag
Stage A
n (%)
Stage B
n (%)
Stage C
n (%)
Group 1 171 -5.44;-3.55 31 (18) 70 (41) 70 (41)
Group 2 205 -3.55;-1.23 41 (20) 87 (42) 77 (38)
Group 3 199 -1.23;:1.44 29 (15) 84 (42) 86 (43)
Group 4 202 1.44; 5.97 19 (9) 89 (44) 94 (47)
Conclsions: Patients from less affluent backgrounds tend to present
at a more advanced Dukes' stage ofCRC. This may explain regional
variations and has implications for public awareness strategy.Oral Presentatons.:WINNER-THEYOUNG INVESTIGATOR'S AWARD 23
PREOPERATIVE CHIEMORADIOTHERAPY FOR
LOCALLY ADVANCED RECTAL CANCER
JIGeh,A Mm" ,RAswd,E Grinuc, RGlym-Joms
mendVr_ Himita,Nh , UL
1ntrducti: Concuentchemoradothrapy (CRT) m unresctable rectl cancer has been
reported to resuk i high respose rames. We report thecomplame, toxiity id d hological
respon rae whenCRTisgiven ie.
Methds: 62 paients with locally aivanced boderline retable or ursectabl (fixed 47;
tthered 9; bulky mobdie 6) adeocarcinom ofthe m (median age 64 yas, range 42-
83) wee treated peavely with CRT. Radiothesray (RI) wasgiven using a 3 ficidplan;
45 Gy in 25 fraction over 33 days (4 patients received 50-53 Gy in 25-29 fractions). 52
jientsreceivedfolic adid 20M#M2 iv bous follwdby 5-fluorouracil (5-EU) 350mg/m2
iv one hour before RT on days 1-5 and 29-33. 10 patents received a continuous 5-EU
infusion 200 mgIm2 via a Hk-man line for 12 weeks conmencing 1-2 weeks prior to
conna_nceme- ofrahtheapy. Patients werereassesed with thereferring surgeon at4weeks
aid operation pled at 6-12 weeks.
Resshl Total comphance ofCRT was achieved in 57paients (92%). Twopatients reied
intuptio of RT for 4 and 7 days for severe diarhoea. Two pat s needed removal of
infected Hickman li WHOgrade 4toxicity occurred in 4patien (6%); diarrhoe 2, skin 1,
neutropnc sepsis 1, all ofwhm recpiedadmissio tohospitaL There were noCRTrelated
deaths. In addimn, 12 patients experienced WHO grade 3 toxicity (moist d) of
pineal skin d9pain hadodtrWHOgrade 3 toxicies (diarrhoea4,tenesn1us I, urinar
frequency 4, vomiting 1). To date, 44 patents have proceeded to operatin; 16 anterior
resection, 22 anterior perineal resection and 6 were found to be unrmesectable (3 intra-
abdomnal metastases; 3 fixed tumours). Hisology is available in all 38 patients who had an
atempted curative resection -pathoogical CR in 6(16%); Dukes' Aim4(11%); Dukes' B in
19 (50%); Dukes C in 9 (23%). Only 3 pautics had involved resection margins. Median
dmaton frm end ofCRTto surgery was 58 days (range 20-137 days).
FBMW Tdin Mobie
pCR 5 1 0
DdLeA 4 0 0
Duhes'B 11 5 3
Dukes!C 7 1 1
After a median follow up interval of 12 months (rage 1-46 months), 12 patients have died
(progressivdmetastatic disease 8;myocardial infarct2,popive cmiato 2).Ofthose
who had aneior orAPresection, only 2 patients (5%) have had local recurence. 3 paients
havereIsndwith& etastae
Con ins: Preoperative CRT using using the above regimes is associated with high
cmplance, acceptabl toxit,goodresectability aidpathogical g in agroup of
paients with advanced rectal cacinoma Theearly rsuts dm a low lcal re nce
rate Dataon surgicalmnbdqandliefunional results/toxicity will beavailableshortly.24 Oral Presentatons: BREAST CANCER 2 (see also pages 14-15)
PATTERNS OF BREAST RELAPSE FOLLOWING
069 BREAST CONSERVING SURGERY AND
RADIOTHERAPY.
B.Magee. E.A.Young. RSvindell Christie Hospital. Manchester UK
The pattem ofbreast relapse has been studied in a prospective
randomised controlled trial of 2 radiotherapy techniques following
breast conserving surgery in clinical stage I breast cancers. 708
patients were randomised to either whole breast radiotherapy using
megavoltage tangential fields (WB group) OR a localised electron
field directed at the tumour bed (LF group)
The WB group has suffered fewer breast relapses than the LF
group: for invasive ductal carcinomas:WB: 31 breast relapses
(10%); LF: 51 breast relapses tl16%)- invasive lobular carcinomas:
WB: 3 breast relapses (100%o): LF: 14 breast relapses (38%)
This reduction in breast relapses for the WB group occurs both
as a reduction in relapses in or close to the same quadrant as the
prmarv tumour e.g. invasive ductal carcinomas: WB: 18(5.5%),
LF: 31(10%o) and also in fewer recurrences elsewhere in the breast:
WB: 5(1.5%). LF: 18(5.5%)
This suggests that the improvement with whole breast
radiotherapy is due to 2 main factors: firstly a reduction in
geographical misses compared to the electron field (LF) group and
secondly an effect ofwhole breast radiotherapy on multicentre foci
ofdisease distant from the primary tumour.
071 EGFR ANDc-erbB-2 EXPRESSION IN BREAST CANCER 071 PROGRESSION. D. Cbona. J. Reeves. T. Cookce. 'W.D.
George. 'E. Mallon. -B. Ozanne and P. Stanton, ULniersir.
Depafument of Swrr. Gtaseow Roral hlifnnar. University Depxarne of Surer. Western
Infirmar. Glaseo% and:Bcaison Institite for Cancer Research- Universits ofGlasnos.
EGFR and c-erbB-2 are being explored as therapeutic targets in
breast cancer. This approach will be enhanced ifit is effective in pre-
invasive as u-ell as invasive disease. We have found that EGFR is
downregulated and c-erbB-2 is overexpressed in 95% of invasive
breast cancers. but little is known about the role ofthese factors in in
situ disease.
In frozen sections of invasive cancers with evidence of ductal
carcinoma in-situ (DCIS). EGFR (n=46) and c-erbB-2 (n=40)
receptor levels were assayed quantitativelI using a radiolabelled
antibody method. Numbers of receptors u-ere determiined by
comparison With cell lines ofknown receptordensity and compared in
each element ofthe tumour.
EGFR and c-erbB-2 expression each varied by a factor ofseveral
thousand. The frequency distributions for expression of both factors
were comparable in DCIS and invasive tumours (Mann-Whitney U
test. EGFR p=0.41. c-erbB-2 p=0.56). Within each tumour. there was
no significant difference in expression of c-erbB-2 or EGFR in the
DCIS and invasive components (Wilcoxon Signed Rank Test. EGFR
p=0.419. c-erbB-2 p=0.343).
These data suggest that alterations in type I growth factor
receptors occur before progression of in-situ disease to invasive
cancer. High levels of c-erbB-2 overexpression in both in-situ and
invasive areas suggest that the c-erbB-2 product is a potential
therapeutic target for the treatment ofbreast cancer at an early- stage.
070 QUANrITATION OF C-ERBB-2 IN PRIMARY BREAST CANCER
070 GENE AMPUFlCATION IS NOT THE WHOLE PICTJRE, D. Chcao. J
Rws. T Cooix, 'W.D. Gemre, E. NfM, 2B Om= mdP Smci
Unrssy Dep OfSuWS ,Gsp Roya Infr-, -y mvwwtyDOq ofSurp, Ween Infmnr.
Gispo md e In forCrRedL,Umvnsi ofGlsgO.
C-erbB-2 fction or high levels of o on are found in about
25% ofbreast ca s and tese pates hae a poor outcome. Usnga a
method infiozensetions we have previously shown that
c-erB-2 is nearly aways vexessed in pnimnry brams cmers with gem
ampficionaccoxmg forapopulationwitheybinghkeveof xexprssxn
Here werepor on the applicatkn of o m a to measure
the c-erbB-2 protean im a laer se of cases (n = 182) with followup exceeding 5
years Disease specific urvival was assessed using Kaplan Mier life table analysis
and log rank tests.
Disease specific survi-val and c-erbB-2 expression
_ o
D
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88.!. oftuma s overxessed c-erbB-2. 23/ had greater than 20 ti
normal pression, which we have previouly shown, ind es amplification at this
koaLs These cams had a gficantly poor suival than the res of the
overessOrs (p<0.0001). Ir Ofcase had lower c-eb2 e o m
to normal breast tiue These paents also had a poorer prognoss thn the non-
anVlifed ov xessors (p<0.0001)
Quanttative est_mations ofc-erbB-2 in frozen sectom alow m e
of the protean mi neary al cases whereas parffin section
provides 4ectiRve da on only the ighest exsso. Tumours with down
reguated c-erb2 ave as poor a pronoss as thoe with eneami n
oftheprtein
072 MRI IN THE ROUTlINE REE-
DIMENSIONAL PLANNING OF BREAST CANCER E.C.
Whipp, R Hartley-Davies, S. Dunne, A Gee, M. Keen and M.
Hafliwell. United Bristol Heltbcare Tnrst, Bristol BS1 6SY, UK.
Objective To determine the accuracy of conventional breast plans
usin images from an open MR[ scanner.
Methods: Having resolved the distortion problems inhaent in MRI by
using software written within our deatment, we have been able to
feed MRI images made in several planes directly into our planing
systenm
Results: Afterpforming 30 MRI scans of breast, chest wall and
cervico-axillary chain, also the heart, limits of breast tisue,
chest wall thks, tmKor exsin sites and the postion ofmtemal
mammary nodes in breast cancer patients in the treate position
using an open MI scanner, we found nearly 50%/ of convenional
plans had to be amended. As a result, we now perform rouine MRI
before theplanning session whenever possible.
CoadaQtons: 10/. oftumour cavities were missed by ta al felds.
Post-operative tumour cavie were difficult to locate and bolus
distorts the breast and moves these cavities further. Theterritory ofthe
cervico-axillary chain is often wider than expected and the three-
dimensional anatomy of patients in this part of the body varies
tenendously.Oral Presentatons: BREAST CANCER 2 (see also pages 14-15) 25
073 ROLEOF BRCA2 IN DNA REPAIR:
IMPUCATIONS FOR BREAST CARCINOGENESIS AND
THERAPY. Gillian Ross; A. Tutt; D.Bertwhistlel;
A.Ashworthl Academic RaPiotheray aMd Oncology Unit; Section of
Gene Fucton and Regualaon, Chester Beaty Labs, lnshttte of Cancer
Research,London.
Germline mutabons in the BRCA1 and BRCA2 genes may
account for a signrfcant proportion of te 5% of early onset
cases of breast cancerAn increasing body of evience suggests
that these cancer predisposon genes may have a citciai
functon in both DNA repair and maintenance of genomic
stability.
We have assessed DNA repair in fibrobiasts derived from
knockout mice of genotype Brca 2+/+.+/-,and -/-; animals were
generated by siting an insertonal mutation in exon 11 giving rise
to a truncated protein, by homoxogous recombinaion and
standard ES technolgy. The phenotype incLudes increased risk
of embryonic lethality, skeletal growth defects, failure of germ
cell maturaton, and early onset of thymic lymphoma. Cells fail to
proiferate in vitro, associated with overexpression of p53 and
p21/WAF1. We hypothessed that the observed growth arrest
and acvation of genes involved in DNA damage signal
transduction might imply an upstream function for BRCA2 in
DNA repair. Using neutral cell gel electrophoresis, we have
demonstrated a defect in DNA double strand break rejining in
vitro, in fibroblsts derived from Brca2-/- animals after ionising
radiaton. This data is the first direct biochemical evience of a
role for BRCA2 in DNA repair. Continuing our
genetc/biohmical approach,we will use the Brca 2 +/-
genotype as a mode of the human germline state to investgate
interaction with oter genes implicated in breast carcinogenesis
(p53,AT) and cross breed to a transgenic mutatona reporter
strain(Mutamouse) to investgate enviromental factors
influencing mutability and carcinogenesis, and help design
intervention strategies relevent to the dinic.
A PROSPECTIVE RANDOMIZED STUDY OF MITOXANTRONE (M)
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The combinatiaon of Fluorourcil(F), Cytoxan(C), with either Adramycin(A) or
Epirubicin(E) (FAC/FEC) is considered as gold standard regxmn in ABC.We
performed a ranoiized trial conparig this regmien (F: 500 mg/rn2, A or E: 50
mg/in2, C: 500 mg/ml on day 1) to the combination M.V. (M: 12 mg/r2. V: 25
mg/Tn on day 1 andV: 25 mg/fn2 on day 8 ifneutrphils> 1000I O m3). Treatment
cycles were repeated every 21 days. Stratification was based upon prior adjuvant
CT. 281 patients (pts) were randomized between FAC/FEC (139 pts) and MV
(142 pts). 92 pts had received prior adjuvant CT (77 with anthracyclm). 82 00 of
pts had visceral metasases and the mediannunber ofmetastatic sites w-as 2 (1-7).
Overall 841 FAC/FEC cycles and 698 MV cycles were given(medanpt- 6 and 5
respectvely). The mean relative dose mtensity was 95 O/o, 96 00 96 % for
FAC/FEC and 92 %, 77 % for MV. Haenatological toxicity delayed reatment
cycles im 17 % (FAG/FEC) and 27 % (MV) and let to witlxaw V on day 8 in 29
%. Febrile rneuropenia req d hospitalisation in 2 % (FAC/FEC) and 15 00
(MV) of pts (p=0.001) and antibiotics in 0.6 % and 6 % of pts. Non
haernatological toxicity was m favor of MV for grades 3 and 4 nausea and
vomitmg (N/V) (16 % vs 8 %: p = 0.03) and for grade 3 alopecia (30 % vs 70: p
= 0.0001). Mostly maior cardiac events occured im 19 pts (10 FACGFEC, 9 MV).
The objective response rate (ORR) of the whole population was smilar
FACGFEC: 33.3 % vs MV: 35.5 % (p = 0.014). For pts who have received pnor
adjuvant CT the ORR was higher in MV arm (33 % vs 13 %: p = 0.025). For
those who had not thee is a slight non statistically significant trend in favor of
FAC/FEC arm (43 % vs 35 %: p = 0.25). Median duration of response was 10
months (1-24) for FACGFEC and 7 months (1-27) for MV. Time to progression
(CTP) and overall survival (OS) were notdifferent in the two groups (p = 0.79 and
p = 0.27 respectively) but showed the same divergence when pnror adjuvant
therapy was taken mto accowxt Wen used as first line etment in pts with
iestatic breast cancer, MV and FAC/FEC have no different efficacy in term of
ORR, TMl and OS for the whole populaion However, for pts with previous
adjuvant CT, MV combinaton seems to besperor. Haematlogical toxicitywas
higher forthisregimen while nonhaematological toxicity(N/V, alopecia) was less
frequent
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NEGATIVE BREAST CANCERS. Y S. Wang'. Q. Liu. X. P. Hao'.
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This study examined the prognostic value of a range of tumour
markers in patients with node negative breast cancer.
Tissues from patients with breast cancer (n=116) w-ere studied
retrospectively. The age and menopausal status of the patients. tumour
size. type and grades. oestrogen receptor (ER) (immunohistochemistry.
IHC). DNA ploidy (flow cytometry. FC). S phase fraction (SPF) (FC).
proliferative index (PI) (FC). cathepsin D (IHC). mutant p53 (LHC).
CD44v (FC). c-erbB2 (IHC). ras p2l (FC) were assessed and
correlated with 10 year overall survival. CD44v. p53. cathepsin D. as
well as the size. histopathological type. nuclear (NG)/histological (HG)
grades. ER. SPF and PI were found to have a univariant prognostic
relationship with survival. A prognostic index was obtained with the
Cox regression model: index=0.075 Xsize-O-0.196XNG+0.146
XER+0.059XSPF+0.241 x cath D+0.270xp53+0.127XCD44v.
These 7 parameters were found to be independent prognostic factors
for survival. Patients were divided into three groups according to the
prognostic index thus calculated: i. index<l.6 (n=60): 10 yr survival
91.7%: ii. l.6<index.l.9 (n=24): 10 vr survival 58.3%7: iii. index>l.9
(n=32): 10 yr survival 15.6%. compared with 10 yr overall sunrival
63.8% of all the patients in this study.
It is concluded that tumour markers p53. CD-4v. and cathepsin D
as well as tumour size. nuclear grade. ER. and SPF can be used as
markers for the prognosis ofpatients with lymph node negative breast
cancer.